UbE2D3、UbE2C及hTERT的表达与宫颈癌分期、分级及预后的关系探讨
|
摘要
目的：探讨hTERT、UbE2D3及UbE2C在宫颈癌组织中的表达情况,分析三者基因编码蛋白在宫颈癌发生、发展过程中的作用和三者在宫颈癌中表达的相关性,以及hTERT、UbE2D3及UbE2C与宫颈癌临床病理因素之间的关系,研究三者对宫颈癌预后的影响,并探讨相关的分子病理学机制。
材料与方法：回顾性分析2002年～2012年间武汉大学中南医院病理科保存的经手术切除宫颈癌蜡块组织标本173例,采用免疫组化法检测hTERT、UbE2D3及UbE2C在宫颈癌组织中的表达情况,hTERT、UbE2D3及UbE2C蛋白在不同分期不同级别宫颈癌组织中的表达阳性率的比较应用x~2检验和IFisher确切概率法,hTERT、UbE2D3及UbE2C对宫颈癌患者预后的影响采用Kaplan-Meier法及Log rank检验,hTERT、UbE2D3及UbE2C两者的表达相关性评价应用Kendall's tau-b等级相关分析,影响宫颈癌患者的预后多因素分析采用Cox多因素分析法,P<0.05为差异有统计学意义。
结果：hTERT蛋白阳性信号主要分布在细胞核中,而UbE2D3在细胞核及细胞浆中均有分布。宫颈癌组织中hTERT蛋自表达与患者年龄、病理类型、分期、分级无关,P>0.05,但与宫颈癌淋巴结转移密切相关,即有淋巴结转移组hTERT及阳性表达率显著高于无淋巴结转移组,P<0.05,同时UbE2D3蛋白表达与患者年龄、病理类型、分级无关,P>0.05,但与宫颈癌的分期及淋巴结转移相关,即分期晚者UbE2D3蛋白表达较分期早者低,同时,有淋巴结转移组UbE2D3阴性表达率显著高于无淋巴结转移组,P<0.05。UbE2C蛋白阳性信号在细胞核及细胞浆中均有分布。宫颈癌组织中UbE2C蛋白表达均与患者年龄、病理类型无关,P>0.05,但其表达与宫颈癌分期、分级、淋巴结转移密切相关,即分期高组UbE2C蛋白表达量显著高于分期较低组,分化程度高组UbE2C表达量显著低于分化程度低组,有淋巴结转移组UbE2C蛋白阳性表达率显著高于无淋巴结转移组,P<0.05。UbE2D3、UbE2C及hTERT的表达均与宫颈癌患者的预后相关,即UbE2D3表达量低的宫颈癌患者预后较表达量高者差,UbE2C及hTERT表达量高者较表达量低者预后差,差异具有统计学意义,P<0.05。宫颈癌组织中hTERT及UbE2D3蛋白表达呈负相关,有统计学意义(rk=-0.330,P<0.001),宫颈癌组织中hTERT及UbE2C蛋白表达呈正相关,有统计学意义(rk=0.483,P<0.001)。同时,Cox多因素法分析显示,hTERT蛋白表达水平,UbE2D3蛋白表达水平、UbE2C蛋白表达水平、肿瘤分级及淋巴结转移是影响宫颈癌预后的独立因素。
结论：1、hTERT在细胞中的过度激活在宫颈癌的发生发展的过程中起着重要的作用。hTERT蛋白可以作为宫颈癌诊断和预后判断的分子标志物,是影响宫颈癌预后的独立因素,高hTERT表达提示宫颈癌患者预后不良。2、UbE2D3是宫颈癌发生发展过程中的保护性因素,与hTERT的表达呈负相关。UbE2D3是影响宫颈癌预后的独立因素,低UbE2D3表达提示宫颈癌患者预后不良。3、UbE2C与宫颈癌的发生发展,分期分级及预后密切相关,UbE2C不仅参与了宫颈癌变的起始阶段,同时也参与了癌变的全部进程,UbE2C与hTERT的表达正相关,UbE2C是影响宫颈癌患者预后的独立因素,高UbE2C表达提示宫颈癌患者预后不良。
Objective Evaluate the expression of hTERT.UbE2D3, and UbE2C in cervical cancer tissue and analyze the role of these genes coding protein in the process of development and the correlation in cervical cancer, and the relationship between hTERT, UbE2D3,UbE2C and clinical pathological factors of cervical cancer, their effect on the prognosis of cervical cancer research, and explore the related mechanism of molecular pathology.
Materials and Methods Clinical data of173cases of surgical tissue specimens from wax of patients with cervical cancer saved by the department of pathology of wuhan university zhongnan hospital between2002-2012were analyzed restrospectively. We use the immunohistochemical staining to detect the expression of hTERT, UbE2D3and UbE2C protein. We use SPSS17.0statistical software to do the statistical analysis, we use x2test and Fisher's exact probability method to analyze different expression levels of hTERT, UbE2D3and UbE2C in different stages,classification,grade in cervical cancer tissue, hTERT, UbE2D3and UbE2C's influence on the prognosis of patients with cervical cancer by Kaplan Meier-method and the Log rank test, the evaluation application of the correlation of the expression of hTERT and UbE2D3,UbE2C using Kendall's tau-b rank correlation analysis, the factors affecting the prognosis of patients with cervical cancer using Cox multiple factors analysis, P<0.05for the difference was statistically significant.
Results hTERT protein positive signals are mainly distributed in the nucleus, and UbE2D3are distributed both in the nucleus and cytoplasm. hTERT protein expression in cervical cancer tissue is not closely related to the patients age, pathological type, stage, grade, P>0.05, but is closely related to the cervical lymph node metastasis, which means positive expression rate of lymph node metastasis group hTERT was significantly higher than that of group without lymph node metastasis, P<0.05, at the same time UbE2D3protein expression has nothing to do with the patient age, pathology type, grade, P>0.05, but is associated with cervical cancer staging and lymph node metastasis,the later stage UbE2D3protein expression was lower than those of early stage early, at the same time, lymph node negative metastasis group UbE2D3expression rate was significantly higher than that of group lymph node metastasis, P<0.05). UbE2C protein positive signals were distributed in the nucleus and cytoplasm. UbE2C protein expression in cervical cancer tissue has nothing to do with patient's age. pathology type. P>0.05, but its expression is closely related to the cervical cancer staging, grading and lymph node metastasis,which means the stage high group UbE2C protein expression are significantly higher than the low group, high degree of differentiation group UbE2C expression quantity is significantly lower than the low degree of differentiation, lymph node metastasis group UBE2C protein positive expression rate was significantly higher than that of group without lymph node metastasis, P<0.05). The expression of UbE2D3UbE2C and hTERT are associated with the prognosis of patients with cervical cancer.means that the lower the expression of UbE2D3is,the cervical cancer patients prognosis is the poorer, the higher the expression quantity of UbE2C and hTERT is,the poorer the prognosis is, the difference is statistically significant, P<0.05. The correlation between expression of hTERT and UbE2D3protein inCervical cancer tissue was statistically significant (fairly rk=0.330, P<0.001), and the expression relationship between UbE2C and hTERT protein in cervical cancer tissue were positively correlated,(fairly rk=0.483, P<0.001). At the same time, Cox multiple factor method analysis shows that protein expression levels of hTERT, UbE2D3,UbE2C, tumor grade and lymph node metastasis is the independent factors which affecting the prognosis of cervical cancer.
Conclusions1,The excessive activation of hTERT in cells in the occurrence and development of cervical cancer plays an important role in the process. HTERT protein can be used as a cervical cancer diagnostic and prognostic molecular markers, were the independent factors influencing the prognosis of cervical cancer, high hTERT expression suggests poor prognosis of cervical cancer patients.2, UbE2D3is cervical cancer occur in the development of protective factors, and negatively correlated with the expression of hTERT. UbE2D3is the independent factors affecting the prognosis of cervical cancer, low UbE2D3expression suggests poor prognosis of cervical cancer patients.3, UbE2C development, with the incidence of cervical cancer staging classification and prognosis is closely related to UbE2C is not only involved in the initial stage of cervical cancer become, all at the same time also participated in the cancer process, UbE2C is positively related with the expression of hTERT, UbE2C is the independent factors affecting the prognosis of patients with cervical cancer, high UbE2C expression suggests poor prognosis of cervical cancer patients.
材料与方法：回顾性分析2002年～2012年间武汉大学中南医院病理科保存的经手术切除宫颈癌蜡块组织标本173例,采用免疫组化法检测hTERT、UbE2D3及UbE2C在宫颈癌组织中的表达情况,hTERT、UbE2D3及UbE2C蛋白在不同分期不同级别宫颈癌组织中的表达阳性率的比较应用x~2检验和IFisher确切概率法,hTERT、UbE2D3及UbE2C对宫颈癌患者预后的影响采用Kaplan-Meier法及Log rank检验,hTERT、UbE2D3及UbE2C两者的表达相关性评价应用Kendall's tau-b等级相关分析,影响宫颈癌患者的预后多因素分析采用Cox多因素分析法,P<0.05为差异有统计学意义。
结果：hTERT蛋白阳性信号主要分布在细胞核中,而UbE2D3在细胞核及细胞浆中均有分布。宫颈癌组织中hTERT蛋自表达与患者年龄、病理类型、分期、分级无关,P>0.05,但与宫颈癌淋巴结转移密切相关,即有淋巴结转移组hTERT及阳性表达率显著高于无淋巴结转移组,P<0.05,同时UbE2D3蛋白表达与患者年龄、病理类型、分级无关,P>0.05,但与宫颈癌的分期及淋巴结转移相关,即分期晚者UbE2D3蛋白表达较分期早者低,同时,有淋巴结转移组UbE2D3阴性表达率显著高于无淋巴结转移组,P<0.05。UbE2C蛋白阳性信号在细胞核及细胞浆中均有分布。宫颈癌组织中UbE2C蛋白表达均与患者年龄、病理类型无关,P>0.05,但其表达与宫颈癌分期、分级、淋巴结转移密切相关,即分期高组UbE2C蛋白表达量显著高于分期较低组,分化程度高组UbE2C表达量显著低于分化程度低组,有淋巴结转移组UbE2C蛋白阳性表达率显著高于无淋巴结转移组,P<0.05。UbE2D3、UbE2C及hTERT的表达均与宫颈癌患者的预后相关,即UbE2D3表达量低的宫颈癌患者预后较表达量高者差,UbE2C及hTERT表达量高者较表达量低者预后差,差异具有统计学意义,P<0.05。宫颈癌组织中hTERT及UbE2D3蛋白表达呈负相关,有统计学意义(rk=-0.330,P<0.001),宫颈癌组织中hTERT及UbE2C蛋白表达呈正相关,有统计学意义(rk=0.483,P<0.001)。同时,Cox多因素法分析显示,hTERT蛋白表达水平,UbE2D3蛋白表达水平、UbE2C蛋白表达水平、肿瘤分级及淋巴结转移是影响宫颈癌预后的独立因素。
结论：1、hTERT在细胞中的过度激活在宫颈癌的发生发展的过程中起着重要的作用。hTERT蛋白可以作为宫颈癌诊断和预后判断的分子标志物,是影响宫颈癌预后的独立因素,高hTERT表达提示宫颈癌患者预后不良。2、UbE2D3是宫颈癌发生发展过程中的保护性因素,与hTERT的表达呈负相关。UbE2D3是影响宫颈癌预后的独立因素,低UbE2D3表达提示宫颈癌患者预后不良。3、UbE2C与宫颈癌的发生发展,分期分级及预后密切相关,UbE2C不仅参与了宫颈癌变的起始阶段,同时也参与了癌变的全部进程,UbE2C与hTERT的表达正相关,UbE2C是影响宫颈癌患者预后的独立因素,高UbE2C表达提示宫颈癌患者预后不良。
Objective Evaluate the expression of hTERT.UbE2D3, and UbE2C in cervical cancer tissue and analyze the role of these genes coding protein in the process of development and the correlation in cervical cancer, and the relationship between hTERT, UbE2D3,UbE2C and clinical pathological factors of cervical cancer, their effect on the prognosis of cervical cancer research, and explore the related mechanism of molecular pathology.
Materials and Methods Clinical data of173cases of surgical tissue specimens from wax of patients with cervical cancer saved by the department of pathology of wuhan university zhongnan hospital between2002-2012were analyzed restrospectively. We use the immunohistochemical staining to detect the expression of hTERT, UbE2D3and UbE2C protein. We use SPSS17.0statistical software to do the statistical analysis, we use x2test and Fisher's exact probability method to analyze different expression levels of hTERT, UbE2D3and UbE2C in different stages,classification,grade in cervical cancer tissue, hTERT, UbE2D3and UbE2C's influence on the prognosis of patients with cervical cancer by Kaplan Meier-method and the Log rank test, the evaluation application of the correlation of the expression of hTERT and UbE2D3,UbE2C using Kendall's tau-b rank correlation analysis, the factors affecting the prognosis of patients with cervical cancer using Cox multiple factors analysis, P<0.05for the difference was statistically significant.
Results hTERT protein positive signals are mainly distributed in the nucleus, and UbE2D3are distributed both in the nucleus and cytoplasm. hTERT protein expression in cervical cancer tissue is not closely related to the patients age, pathological type, stage, grade, P>0.05, but is closely related to the cervical lymph node metastasis, which means positive expression rate of lymph node metastasis group hTERT was significantly higher than that of group without lymph node metastasis, P<0.05, at the same time UbE2D3protein expression has nothing to do with the patient age, pathology type, grade, P>0.05, but is associated with cervical cancer staging and lymph node metastasis,the later stage UbE2D3protein expression was lower than those of early stage early, at the same time, lymph node negative metastasis group UbE2D3expression rate was significantly higher than that of group lymph node metastasis, P<0.05). UbE2C protein positive signals were distributed in the nucleus and cytoplasm. UbE2C protein expression in cervical cancer tissue has nothing to do with patient's age. pathology type. P>0.05, but its expression is closely related to the cervical cancer staging, grading and lymph node metastasis,which means the stage high group UbE2C protein expression are significantly higher than the low group, high degree of differentiation group UbE2C expression quantity is significantly lower than the low degree of differentiation, lymph node metastasis group UBE2C protein positive expression rate was significantly higher than that of group without lymph node metastasis, P<0.05). The expression of UbE2D3UbE2C and hTERT are associated with the prognosis of patients with cervical cancer.means that the lower the expression of UbE2D3is,the cervical cancer patients prognosis is the poorer, the higher the expression quantity of UbE2C and hTERT is,the poorer the prognosis is, the difference is statistically significant, P<0.05. The correlation between expression of hTERT and UbE2D3protein inCervical cancer tissue was statistically significant (fairly rk=0.330, P<0.001), and the expression relationship between UbE2C and hTERT protein in cervical cancer tissue were positively correlated,(fairly rk=0.483, P<0.001). At the same time, Cox multiple factor method analysis shows that protein expression levels of hTERT, UbE2D3,UbE2C, tumor grade and lymph node metastasis is the independent factors which affecting the prognosis of cervical cancer.
Conclusions1,The excessive activation of hTERT in cells in the occurrence and development of cervical cancer plays an important role in the process. HTERT protein can be used as a cervical cancer diagnostic and prognostic molecular markers, were the independent factors influencing the prognosis of cervical cancer, high hTERT expression suggests poor prognosis of cervical cancer patients.2, UbE2D3is cervical cancer occur in the development of protective factors, and negatively correlated with the expression of hTERT. UbE2D3is the independent factors affecting the prognosis of cervical cancer, low UbE2D3expression suggests poor prognosis of cervical cancer patients.3, UbE2C development, with the incidence of cervical cancer staging classification and prognosis is closely related to UbE2C is not only involved in the initial stage of cervical cancer become, all at the same time also participated in the cancer process, UbE2C is positively related with the expression of hTERT, UbE2C is the independent factors affecting the prognosis of patients with cervical cancer, high UbE2C expression suggests poor prognosis of cervical cancer patients.
引文
[1]Parkin DM.The global health burden of infection-associated cancers in the year 2002[J].International Journal of Cancer,2006,118:3030-3044.
[2]WHO 2010.Viral cancer. Human papillomavirus [EB/OL], http://www.who.int/ vaccine-research/diseases/viral-cancers/en/index3.html.
[3]Parkin DM,Bray F.Ferlay J,Pisani P,Estimating the world emloer burden:GLOBOCAN 2000[J].ht Cancer,2001,94:153-156.
[4]黄莫婉.宫颈癌研究新进展.荸庆医学,2006.35：2185—2187.
[5]Wang SS,Sherman ME,Hildesheim A,et al.Cervical adenocarcinoma and squamous cell carcinoma incidence trends among white women and black women in the United States for 1976-2000[J].Cancer,2004,100:1035-1044.
[6]吴少雄.子宫颈癌放射治疗的几个热点问题[J].广东医学,2004,25(2)：120-121.
[7]Moyzis RK,et al.Proc Natl Acad sci USA,1988,85:6622-6626.
[8]Campbell LJ, Fidler C, Eagleton H, et al. hTERT, the catalytic component of telomerase, is downregulated in the haematopoietic stem cells of patients with chronic myeloid leukaemia. Leukemia,2006,20:671-9.
[9]Love WK, Berletch JB, Andrews LG et al. Epigenetic regulation of telomerase in retinoid-induced differentiation of human leukemia cells. Int J Oncol,2008,32(3):625-31.
[10]Linger J,Hughes TR,Shevchenko A,et al.Reverse transcriptase motifs in the catalytic subunit of telomerase [J].Science,1997,276 (5312):561-567.
[11]Daling JR,Madeleine MM,Mc Knight B,et al.The relationship of human papillomavirus-related cervical tumors to cigarette smoking,oral contraceptive use,and prior herpes simplex virus type 2 infection[J].Cancer Epidemiol Biomarkers Prev,1996,5:541-548.
[12]Bulk S, Berkhof J, Bulkmans NW,et al. Preferential risk of HPV16 for squamous cell carcinoma and of HPV18 for adenocarcinoma of the cervix compared to women with normal cytology in The Netherlands. Br J Cancer,2006 Jan 16;94(1):171-5.
[13]Kanaya T,Kyo S,Hamada K,et al. Adenoviral expression of p53 represses telomerase activity through down-regulation of human telomerase reverse transcriptase transcription[J]. Clin Cancer Res,2000,6(4):1239-1247.
[14]Jeong Seo E, Jang Kim H, Jae Lee C,et al.The role of HPV oncoproteins and cellular factors in maintenance of hTERT expression in cervicalcarcinoma ceHs.Gynecol Oncol,2004,94:40-47.
[15]Toshikuni N, Nouso K, Higashi T,et al. Expression of telomerase-associated protein 1 and telomerase reverse transcriptase in hepatocellular carcinoma. Br J Cancer.2000 Feb;82(4):833-7.
[16]Jong HS, Park YI, Kim S,et al. Up-regulation of human telomerase catalytic subunit during gastric carcinogenesis. Cancer.1999 Aug 15;86(4):559-65.
[17]CM Counter,M Meyerson,, EN Eaton,et al. Telomerase activity is restored in human cells by ectopic expression of hTERT(hEST2),the catalytic subunit of telomerase [J].Oncogene,Mar 1998,16(9):1217-22.
[18]A Wu. M Ichihashi,M Ueda,et al. Correlation of the expression of human teIomerase subunits with telomerase activity in normal skin and skin tumors [J]. Cancer,Nov 1999,86 (10):2038-44.
[19]Batinac T, Zamolo G, Hadzisejdic I. Telomerase in antitumor response. Med Hypotheses, 2007,68:128-30.
[20]Zawrocki A, Izycka-Swieszewska E, Papierz W,et al. Analysis of the prognostic significance of selected morphological and immunohistochemical markers in ependymomas, with literature review. Folia Neuropathol,2011;49(2):94-102.
[21]Zhang PH, Tu ZG, Yang MQ,et al. Experimental research of targeting hTERT gene inhibited in hepatocellular carcinoma therapy by RNA interference[J]. Ai Zheng,2004 Jun;23(6):619-25.
[22][39] Pallini R, Sorrentino A, Pierconti F, et al. Telomerase inhibition by stable RNA interference impairs tumor growth and angiogenesis in glioblastoma xenografts[J]. Int J Cancer,2006,118(9):2158-67.
[23]Calvin BH. Telomerase and cancer therapeutics. Nat Rev Cancer,2008,8(3):167-79.
[24]Li H, Zhou J, Miki J, et al. Telomerase-immortalized nonmalignant human prostate epithelial cells retain the properties of multipotent stem cells[J]. Exp Cell Res,2008, 314(l):92-102
[25]Lai SR, Phipps SM, Liu L, et al. Epigenetic control of telomerase and modes of telomere maintenance in aging and abnormal systems[J]. Front Biosci,2005,10:1779-96.
[26]Holm R, Skomedal H, Helland A,et al. Immunohistochemical analysis of p53 protein overexpression in normal, premalignant, and malignant tissues of the cervix uteri. J Pathol,1993 Jan; 169(1):21-6.
[27]Kanaya T,Kyo S,Hamada K,et al. Adenoviral expression of p53 represses telomerase activity through down-regulation of human telomerase reverse transcriptase transcription[J]. Clin Cancer Res,2000,6(4):1239-1247.
[28]Lai SR, Cunningham AP, Huynh VQ,et al. Evidence of extra-telomeric effects of hTERT and its regulation involving a feedback loop[J]. Exp Cell Res.2007 Jan 15;313(2):322-30.
[29]Shats I, Milyavsky M, Tang X.et al. p53-dependent down-regulation of telomerase is mediated by p21waf1[J].J Biol Chem.2004 Dec 3:279(49):50976-85.
[30]Xu DW,Wang Q,Gruber A, et al. Downregulation of telomerase reverse transcriptase mRNA expression by wild type p53 in human tumor cells. Oncogene.2000,19:5123-33.
[31]Beitzinger M, Oswald C, Beinoraviciute-Kellner R, et al.Regulation of telomerase activity by the p53 family member p73. Oncogene,2006,25:813-26.
[32]Mukherjee G, Freeman A, Moore R,et al. Biologic factors and response to radiotherapy in carcinoma of the cervix[J]. Int J Gynecol Cancer,2001 May-Jun;11(3):187-93.
[33]Suzuki Y, Nakano T, Ohno T, Oka K. Comparison of the radiobiological effect of carbon ion beam therapy and conventional radiation therapy on cervical cancer[J]. J Radiat Res,2008 Sep;49(5):473-9.
[34]Ishikawa H, Mitsuhashi N. Sakurai H,et al. The effects of p53 status and human papillomavirus infection on the clinical outcome of patients with stage ⅢB cervical carcinoma treated with radiation therapy alone[J]. Cancer.2001 Jan 1;91(1):80-9.
[35]Wickliffe K, Williamson A, Jin L, et al. The multiple layers of ubiquitin-dependent cell cycle control[J]. Chem Rev,2009,109(4):1537-1548.
[36]Hoeller D, Hecker CM, Dikic I. Ubiquitin and ubiquitin-like proteins in cancer pathogenesis[J]. Nat Rev Cancer,2006,6(10):776-788.
[37]Saville MK, Sparks A, Xirodimas DP, Wardrop J, Stevenson LF, Bourdon JC, et al. Regulation of p53 by the ubiquitin-conjugating enzymes UbcH5B/C in vivo. J Biol Chem,2004;279:42169-42181.
[38]Gonen H, Bercovich B, Orian A, Carrano A, Takizawa C, Yamanaka K, et al. Identification of the ubiquitin carrier proteins, E2s, involved in signal-induced conjugation and subsequent degradation of ikappaBalpha. J Biol Chem,1999;274:14823-14830.
[39]Okamoto Y, Ozaki T. Miyazaki K, et al. UbcH10 is the cancer-related E2 ubiquitin-conjugating enzyme[J]. Cancer Res,2003,63(14):4167-4173.
[40]Collado M, Garcia V, Garcia JM, Alonso I,et al. Genomic profiling of circulating plasma RNA for the analysis of cancer[J]. Clin Chem,2007 Oct;53(10):1860-3.
[41]Mohammed N, Rodriguez M, Garcia V,etal. EPAS1 mRNA in plasma from colorectal cancer patients is associated with poor outcome in advanced stages[J].Oncol Lett,2011 Jul;2(4):719-724.
[42]Ryan, K. M., Phillips, A. C., and Vousden, K. H. (2001) Curr. Opin. Cell Biol, 2013.332-337
[43]Oren, M. (2003) Cell Death Differ,10,431-442.
[44]Mittal MK, Singh K. Misra S, Chaudhuri G. SLUG-induced elevation of D1 cyclin in breast cancer cells through the inhibition of its ubiquitination[J]. J Biol Chem,2011 Jan 7;286(1):469-79.
[45]Ricke RM, van Ree JH, van Deursen JM. Whole chromosome instability and cancer:a complex relationship[J]. Trends Genet,2008,24(9):457-466.
[46]Van Ree JH, Jeganathan KB, Malureanu L, van Deursen JM.Overexpression of the E2 ubiquitin-conjugating enzyme UbcH10 causes chromosome missegregation and tumor formation. J Cell Biol,2010;188(1):83-100.
[47]Wagner KW, Sapinoso LM, E1-Rifai W, et al. Overexpression, genomic amplification and therapeutic potential of inhibiting the UbcH10 ubiquitin conjugase in human carcinomas of diverse anatomic origin[J]. Oncogene,2004,23(39):6621-6629.
[48]Chen S, Chen Y, Hu C, et al. Association of clinicopathological features with UbcH10 expression in colorectal cancer[J]. J Cancer ResClin Oncol,2010,136(3):419-426.
[49]Berlingieri MT, Pallante P, Sboner A,et al. UbcH10 is overexpressed in malignant breast carcinomas[J]. Eur J Cancer,2007 Dec;43(18):2729-35.
[50]Fujita T, Ikeda H, Taira N, et al. Overexpression of UbcH10 alternates the cell cycle profile and accelerate the tumor proliferation in colon cancer[J]. BMC Cancer,2009,9: 87.
[51]Fujita T, Ikeda H, Kawasaki K, et al. Clinicopathological relevance of UbcH10 in breast cancer[J]. Cancer Sci,2009,100(2):238-248.
[52]Shi R, Zhao Z, Gao Y,et al. Analysis and verification of the interaction network of differentially expressed genes in invasive bladder cancer [J]. Nan Fang Yi Ke Da Xue Xue Bao,2010 Aug;30(8):1771-4.
[53]Vasiljevic A, Champier J, Figarella-Branger D, et al. Molecular characterization of central neurocytomas:Potential markers for tumor typing and progression [J]. Neuropathology, 2012 Jul 23.
[54]Li Y, Tang H, Sun Z, et al. Network-based approach identified cell cycle genes as predictor of overall survival in lung adenocarcinoma patients[J]. Lung Cancer,2013 Apr;80(1):91-8.
[55]Kadara H, Lacroix L, Behrens C,et al. Identification of gene signatures and molecular markers for human lung cancer prognosis using an in vitro lung carcinogenesis system[J]. Cancer Prev Res (Phila),2009 Aug;2(8):702-11.
[56]Laurell C, Velazquez-Fernandez D. Lindsten K,et al. Transcriptional profiling enables molecular classification of adrenocortical tumours[J]. Eur J Endocrinol,2009 Jul:161(1): 141-52.
[57]Rajkumar T, Sabitha K, Vijayalakshmi N.et al. Identification and validation of genes involved in cervical tumourigenesis[J]. BMC Cancer,2011 Feb 22;11:80.
[58]Garcia-Escudero R. Martinez-Cruz AB, Santos M, et al. Gene expression profiling of mouse p53-deficient epidermal carcinoma defines molecular determinants of human cancer malignancy[J]. Mol Cancer,2010 Jul 14;9:193.
[59]Fang W, Li X. Jiang Q,et al. Transcriptional patterns, biomarkers and pathways characterizing nasopharyngeal carcinoma of Southern China[J]. J Transl Med,2008 Jun 20;6:32.
[60]May WA, Arvand A, Thompson AD, Braun BS, Wright M, Denny CT. EWS/FLI1-induced manic fringe renders NIH 3T3 cells tumorigenic[J]. Nat Genet, 1997;17(4):495-7.
[61]Sudbo J, Lippman SM, Lee JJ, Mao L, Kildal W, Sudbo A, et al. The influence of resection and aneuploidy on mortality in oral leukoplakia[J].N Engl J Med,2004;350 (14):1405-13.
[62]Hanahan D.Weinberg RA. Hallmarks of cancer:the next generation [J]. Cell,2011;144(5):646-74.
[63]Kadara H, Behrens C, Yuan P, Solis L, Liu D, Gu X, et al. A five-gene and corresponding protein signature for stage-I lung adenocarcinoma prognosis[J]. Clin Cancer Res, 2011; 17(6):1490-501.
[64]Hunter KD, Thurlow JK, Fleming J, Drake PJ, Vass JK, Kalna G, et al. Divergent routes to oral cancer[J]. Cancer Res,2006;66(15):7405-13.
[65]Patel D, McCance DJ. Compromised spindle assembly checkpoint due to altered expression of Ubch10 and Cdc20 in human papillomavirus type 16 E6- and E7-expressing keratinocytes [J]. Virol,2010;84(21):10956-64.
[66]Min W, Wen-li M, Zhao-hui S,et al. Microarray analysis identifies differentially expressed genes induced by human papillomavirus type 18 E6 silencing RNA[J]. Int J Gynecol Cancer.2009 May;19(4):547-63.
[67]Reddy SK, Rape M, Margansky WA, et al. Ubiquitination by the anaphase-promoting complex drives spindle checkpoint inactivation[J]. Nature,2007,446(7138):921-925.
[68]Chen S. Chen Y, Hu C, et al.Association of clinicopathological features with UbcH10 expression in colorectal cancer[J]. J Cancer Res Clin Oncol,2010,136(3):419-426.
[69]Loussouarn D, Campion L, Leclair F, et al. Validation of UBE2C protein as a prognostic marker in node-positive breast cancer[J]. Br J Cancer,2009,101(1):166-173.
[70]Ieta K, Ojima E, Tanaka F, et al. Identification of overexpressed genes in hepatocellular carcinoma, with special reference to ubiquitin-conjugating enzyme E2C gene expression [J]. Int J Cancer,2007,121(1):33-38.
[71]Wagner KW, Sapinoso LM, El-Rifai W, et al. Overexpression, genomic amplification and therapeutic potential of inhibiting the UbcH10 ubiquitin conjugase in human carcinomas of diverse anatomic origin[J]. Oncogene,2004,23(39):6621-6629.
[72]Troncone G, Guerriero E, Pallante P, et al. UbcHIO expression in human lymphomas[J]. Histopathology,2009,54(6):731-740.
[73]Shembade N, Ma A, Harhaj EW. Inhibition of NF-kappaB signaling by A20 through disruption of ubiquitin enzyme complexes[J]. Science,2010 Feb 26;327(5969):1135-9.
[74]Zhang S, Zhou Y, Sarkeshik A,et al. Identification of RNF8 as a ubiquitin ligase involved in targeting the p12 subunit of DNA polymerase δ for degradation in response to DNA damage[J]. J Biol Chem,2013 Feb 1;288(5):2941-50.
[75]Anan T, Nagata Y, Koga H,et al. Human ubiquitin-protein ligase Nedd4:expression, subcellular localization and selective interaction with ubiquitin-conjugating enzymes[J]. Genes Cells,1998 Nov;3(11):751-63.
[76]Page RC, Pruneda JN, Amick J,et al. Structural insights into the conformation and oligomerization of E2-ubiquitin conjugates[J]. Biochemistry.2012 May 22;51(20): 4175-87.
[77]Furukawa M, Ohta T, Xiong Y. Activation of UBC5 ubiquitin-conjugating enzyme by the RING finger of ROC1 and assembly of active ubiquitin ligases by all cullins[J].J Biol Chem,2002 May 3;277(18):15758-65.
[78]Zhang X, Zhao H, Chen Y,et al. Characterization and biological function analysis of the trim3a gene from zebrafish (Danio rerio)[J]. Fish Shellfish Immunol.2012 May;32(5): 621-8.
[79]Bentley ML, Corn JE, Dong KC,et al. Recognition of UbcH5c and the nucleosome by the Bmil/Ringlb ubiquitin ligase complex[J]. EMBO J,2011 Jul 19;30(16):3285-97.
[80]Pruneda JN, Stoll K.E, Bolton LJ,et al. Ubiquitin in motion:structural studies of the ubiquitin-conjugating enzyme-ubiquitin conjugate[J]. Biochemistry,2011 Mar 15; 50(10): 1624-33.
[81]Benirschke RC, Thompson JR, Nomine Y,et al. Molecular basis for the association of human E4B U box ubiquitin ligase with E2-conjugating enzymes UbcH5c and Ubc4[J]. Structure,2010 Aug 11;18(8):955-65.
[82]Nordquist KA, Dimitrova YN, Brzovic PS.et al. Structural and functional characterization of the monomeric U-box domain from E4B[J]. Biochemistry,2010 Jan 19;49(2):347-55.
[83]Xia ZP, Sun L, Chen X, Pineda G,et al. Direct activation of protein kinases by unanchored polyubiquitin chains[J]. Nature,2009 Sep 3;461(7260):114-9.
[84]Kubori T, Hyakutake A, Nagai H. Legionella translocates an E3 ubiquitin ligase that has multiple U-boxes with distinct functions[J]. Mol Microbiol,2008 Mar;67(6):1307-19.
[85]Zhang Y. Higashide WM, McCormick BA, Chen J, Zhou D. The inflammation-associated Salmonella SopA is a HECT-like E3 ubiquitin ligase[J]. Mol Microbiol.2006 Nov;62(3): 786-93.
[86]Zhang S,Zhou Y, Sarkeshik A,et al. Identification of RNF8 as a ubiquitin ligase involved in targeting the p12 subunit of DNA polymerase δ for degradation in response to DNA damage[J]. J Biol Chem,2013 Feb 1;288(5):2941-50.
[87]Ohbayashi N, Okada K, Kawakami S,et al. Physical and functional interactions between ZIP kinase and UbcH5[J]. Biochem Biophys Res Commun,2008 Aug 8;372(4):708-12.
[88]Knipscheer P, van Dijk WJ, Olsen JV, et al. Noncovalent interaction between Ubc9 and SUMO promotes SUMO chain formation[J]. EMBO J,2007 Jun 6;26(11):2797-807.
[89]Starita LM, Pruneda JN, Lo RS,et al. Activity-enhancing mutations in an E3 ubiquitin ligase identified by high-throughput mutagenesis[J]. Proc Natl Acad Sci U S A.2013 Mar 18.
[90]Brzovic PS, Keeffe JR, Nishikawa H.et al. Binding and recognition in the assembly of an active BRCA1/BARD1 ubiquitin-ligase complex[J].Proc Natl Acad Sci U S A,2003 May 13;100(10):5646-51.
[91]Polanowska J, Martin JS, Garcia-Muse T,et al. A conserved pathway to activate BRCA1-dependent ubiquitylation at DNA damage sites[J], EMBO J,2006 May 17,25(10): 2178-88.
[92]Brzovic PS, Lissounov A. Christensen DE,et al. A UbcH5/ubiquitin noncovalent complex is required for processive BRCA1-directed ubiquitination[J]. Mol Cell.2006 Mar 17;21(6):873-80.
[93]Nishito Y, Hasegawa M, Inohara N, Nunez G. MEX is a testis-specific E3 ubiquitin ligase that promotes death receptor-induced apoptosis[J]. Biochem J,2006 Jun 15;396(3):411-7.
[94]Wang Z. Chua HK, Gusti AA.et al. RING-H2 protein WSSV249 from white spot syndrome virus sequesters a shrimp ubiquitin-conjugating enzyme, PvUbc. for viral pathogenesis[J]. J Virol,2005 Jul;79(14):8764-72.
[95]Huang J, Huang Q, Zhou X, Shen MM.et al. The poxvirus p28 virulence factor is an E3 ubiquitin ligase[J]. J Biol Chem,2004 Dec 24;279(52):54110-6.
[96]Rajendra R, Malegaonkar D, Pungaliya P.et al. Topors functions as an E3 ubiquitin ligase with specific E2 enzymes and ubiquitinates p53[J]. J Biol Chem,2004 Aug 27;279(35): 36440-4.
[97]Wu K, Kovacev J, Pan ZQ. Priming and extending:a UbcH5/Cdc34 E2 handoff mechanism for polyubiquitination on a SCF substrate[J]. Mol Cell,2010 Mar 26;37(6): 784-96.
[98]Chiba T, Fujita S, Kubota H, Inoue D,et al. Identification of fasting-induced genes in the rat hypothalamus:relationship with neuroprotection[J]. Ann N Y Acad Sci,2007 Nov;1119:216-26.
[99]Hattori H, Zhang X, Jia Y,et al. RNAi screen identifies UBE2D3 as a mediator of all-trans retinoic acid-induced cell growth arrest in human acute promyelocytic NB4 cells[J]. Blood,2007 Jul 15;110(2):640-50.
[100]Qiu XB, Markant SL, Yuan J, Goldberg AL. Nrdpl-mediated degradation of the gigantic IAP, BRUCE, is a novel pathway for triggering apoptosis[J]. EMBO J,2004 Feb 25;23(4): 800-10.
[101]Yogosawa S, Miyauchi Y, Honda R,et al. Mammalian Numb is a target protein of Mdm2, ubiquitin ligase[J]. Biochem Biophys Res Commun.2003 Mar 21;302(4):869-72.
[102]Murata S, Minami Y, Minami M, Chiba T,et L. CHIP is a chaperone-dependent E3 ligase that ubiquitylates unfolded protein[J]. EMBO Rep,2001 Dec;2(12):1133-8.
[103]Honda Y, Tojo M, Matsuzaki K, Anan T,et al. Cooperation of HECT-domain ubiquitin ligase hHYD and DNA topoisomerase II-binding protein for DNA damage response[J]. J Biol Chem,2002 Feb 1;277(5):3599-605.
[104]Jensen JP, Bates PW, Yang M,et al. Identification of a family of closely related human ubiquitin conjugating enzymes[J]. J Biol Chem,1995 Dec 22;270(51):30408-14.
[105]Tokumoto M, Fujiwara Y, Shimada A,et al. Cadmium toxicity is caused by accumulation of p53 through the down-regulation of Ube2d family genes in vitro and in vivo[J]. J Toxicol Sci,2011 Apr;36(2):191-200.
[106]Jacques C, Baris O, Prunier-Mirebeau D, Savagner F,et al. Two-step differential expression analysis reveals a new set of genes involved in thyroid oncocytic tumors[J]. J Clin Endocrinol Metab,2005 Apr;90(4):2314-20.
[107]Qiu D, Wang WL,et al.Prognostic significance of hTERT mRNA quantitative expression in resected gastric carcinomas[J].Zhonghua Zhong Liu Za Zhi.2011 Jan;33(1):32-6.
[108]Land H,Parada LF,Weinberg RA.Tumorigenic converses of primary embryo fibroblasts reguires at least two cooperating Oncogenes.Nature,1983,304:596-602.
[109]Slamon DJ,deKernion JB,Verma IM,et al.Expression of cellular oncogenes in human Malignancies.Science,1984.224:256-262.
[110]骆福添,胡孟璇.Cox模型在肿瘤预后因素分析中作用.癌症,1991,10：84—87.
[111]袁晓雁,郭社坷,崔文华.影响宫颈癌患者预后因素的临床分析：实用医药杂志,2007-02.No.02.
[112]Torabi M,Aquino SL,Harisinghani MG,et al.Current concepts in lymph node imaging.J Nucl Med,2004,45(9):1509.
[113]Benedef JL,Odicino F,Maisonneuve P,et al.Carcinoma of the cervix uteri.Int J Gynaecol Obstet,2006,95(Suppl 1):43-103.
[114]Peters JM. The anaphase promoting complex/cyclosome:a machine designed to destroy[J]. Nat Rev Mol Cell Biol,2006,7(9):644-656.
[115]Stegmeier F, Rape M, Draviam VM, Nalepa G, Sowa ME, Ang XL, et al. Anaphase initiation is regulated by antagonistic ubiquitination and deubiquitination activities. Nature,2007;446(7138):876-81.
[116]Nasmyth K. How do so few control so many? Cell,2005;120(6):739-46.
[117]Yanagida M. Basic mechanism of eukaryotic chromosome segregation. Philos Trans R Soc Lond B Biol Sci,2005;360(1455):609-21.
[118]Fang G. Checkpoint protein BubR1 acts synergistically with Mad2 to inhibit anaphase-promoting complex. Mol Biol Cell.2002;13(3):755-66.
[119]Walker A, Acquaviva C, Matsusaka T,et al. UbcH10 has a rate-limiting role in G1 phase but might not act in the spindle checkpoint or as part of an autonomous oscillator[J]. J Cell Sci,2008 Jul 15;121(Pt 14):2319-26.
[120]Jiang L, Bao Y, Luo C, et al. Knockdown of ubiquitin-conjugating enzyme E2C/UbcH10 expression by RNA interference inhibits glioma cell proliferation and enhances cell apoptosis in vitro[J]. J Cancer Res Clin Oncol,2010,136(2):211-217.
[121]Hu R, Lu C, Mostaghel EA,et al. Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer[J]. Cancer Res,2012 Jul 15;72(14):3457-62.
[122]Bose MV, Gopisetty G, Selvaluxmy G.et al. Dominant negative Ubiquitin-conjugating enzyme E2C sensitizes cervical cancer cells to radiation[J]. Int J Radiat Biol,2012 Sep;88(9):629-34.
[123]Fristrup N, Birkenkamp-Demtroder K, Reinert T,et al. Multicenter validation of cyclin Dl, MCM7, TRIM29, and UBE2C as prognostic protein markers in non-muscle-invasive bladder cancer[J]. Am J Pathol,2013 Feb;182(2):339-49.
[124]Shan W, Akinfenwa PY, Savannah KB,et al. A small-molecule inhibitor targeting the mitotic spindle checkpoint impairs the growth of uterine leiomyosarcoma[J]. Clin Cancer Res,2012 Jun 15;18(12):3352-65.
[125]Zhao M, Zhang NY, Zurawel A,et al. Degradation of some polyubiquitinated proteins requires an intrinsic proteasomal binding element in the substrates[J]. J Biol Chem,2010 Feb 12;285(7):4771-80.
[126]Townsley FM, Aristarkhov A, Beck S, Hershko A, Ruderman JV.Dominant-negative cyclin-selective ubiquitin carrier protein E2-C/UbcH10 blocks cells in metaphase[J]. Proc Natl Acad Sci USA,1997;94(6):2362-7.
[127]Kim S, Yu H. Mutual regulation between the spindle checkpoint and APC/C[J].Semin Cell Dev Biol,2011;22(6):551-8.
[128]Nath S, Banerjee T, Sen D, Das T, Roychoudhury S. Spindle assembly checkpoint protein Cdc20 transcriptionally activates expression of ubiquitin carrier protein UbcH10[J].J Biol Chem,2011;286(18):15666-77.
[129]Gauci S, Helbig AO, Slijper M, Krijgsveld J, Heck AJ, Mohammed S. Lys-N and trypsin cover complementary parts of the phosphoproteome in a refined SCX-based approach. Anal Chem,2009;81(11):4493-501.
[130]Rape M, Kirschner MW. Autonomous regulation of the anaphasepromoting complex couples mitosis to S-phase entry[J]. Nature,2004;432(7017):588-95.
[131]Jin L,Williamson A, Banerjee S, Philipp I, Rape M. Mechanism of ubiquitin-chain formation by the human anaphase-promoting complex[J]. Cell,2008;133(4):653-65.
[132]David Y, Ziv T, Admon A, Navon A. The E2 ubiquitin-conjugating enzymes direct polyubiquitination to preferred lysines[J]. J Biol Chem,2010;285(12):8595-604.
[133]Wickliffe KE, Lorenz S, Wemmer DE, Kuriyan J, Rape M. The mechanism of linkage-specific ubiquitin chain elongation by a single-subunit E2[J].Cell,2011; 144(5):769-81.
[134]Murray AW. Recycling the cell cycle:cyclins revisited[J]. Cell,2004;116(2):221-34.
[135]Jackson PK, Eldridge AG, Freed E, Furstenthal L, Hsu JY, Kaiser BK, et al. The lore of the RINGs:substrate recognition and catalysis by ubiquitin ligases[J]. Trends Cell Biol, 2000;10(10):429-39.
[136]Jiang F, Basavappa R. Crystal structure of the cyclin-specific ubiquitin-conjugating enzyme from clam, E2-C, at 2.0 A resolution[J].Biochemistry,1999;38(20):6471-8.
[137]Lin Y, Hwang WC, Basavappa R. Structural and functional analysis of the human mitotic-specific ubiquitin-conjugating enzyme, UbcH10[J].J Biol Chem,2002;277(24): 21913-21.
[138]Summers MK, Pan B, Mukhyala K, Jackson PK. The unique N terminus of the UbcH10 E2 enzyme controls the threshold for APC activation and enhances checkpoint regulation of the APC[J]. Mol Cell,2008;31(4):544-56.
[139]Berlingieri MT, Pallante P,Sboner A. Barbareschi M. Bianco M,Ferraro A,et al. UbcH10 is overexpressed in malignant breast carcinomas[J]. Eur J Cancer,2007;43(18):2729-35.
[140]Loussouarn D, Campion L, Leclair F, Campone M, Charbonnel C,Ricolleau G, et al. Validation of UBE2C protein as a prognostic marker in node-positive breast cancer[J]. Br J Cancer,2009;101(1):166-73.
[141]Berlingieri MT, Pallante P, Guida M, Nappi C, Masciullo V, Scambia G, et al. UbcH10 expression may be a useful tool in the prognosis of ovarian carcinomas[J]. Oncogene, 2007;26(14):2136-40.
[142]Chen S, Chen Y, Hu C, Jing H, Cao Y, Liu X. Association of clinicopathological features with UbcH10 expression in colorectal cancer[J]. J Cancer Res Clin Oncol,2010 136(3):419-26.
[143]Ieta K, Ojima E, Tanaka F, Nakamura Y, Haraguchi N, Mimori K,et al. Identification of overexpressed genes in hepatocellular carcinoma, with special reference to ubiquitin-conjugating enzyme E2C gene expression[J]. Int J Cancer,2007;121(1):338.
[144]Laurell C, Velazquez-Fernandez D, Lindsten K, Juhlin C, Enberg U, Geli J, et al. Transcriptional profiling enables molecular classification of adrenocortical tumours[J]. Eur J Endocrinol,2009; 161(1):141-52.
[145]Pallante P, Berlingieri MT, Troncone G, Kruhoffer M, Orntoft TF, Viglietto G, et al. UbcH10 overexpression may represent a marker of anaplastic thyroid carcinomas[J]. Br J Cancer,2005;93(4):464-71.
[146]Jiang L, Huang CG, Lu YC, Luo C, Hu GH, Liu HM, et al.Expression of ubiquitin-conjugating enzyme E2C/UbcH10 in astrocytic tumors[J]. Brain Res,2008; 1201:161-6.
[147]Garnis C, Coe BP, Lam SL, MacAulay C, Lam WL. Highresolution array CGH increases heterogeneity tolerance in the analysis of clinical samples[J]. Genomics,.2005;85(6): 790-3.
[148]Wang Q, Li W, Zhang Y, Yuan X. Xu K, Yu J, et al. Androgen receptor regulates a distinct transcription program in androgenindependent prostate cancer[J]. Cell, 2009;138(2):245-56.
[149]Chen Z, Zhang C, Wu D, Chen H, Rorick A, Zhang X, et al. Phospho-MED1-enhanced UBE2C locus looping drives castration-resistant prostate cancer growth[J]. EMBO J. 2011;30(12):2405-19.
[150]Guerriero E, Ferraro A, Desiderio D, Pallante P, Berlingieri MT, Iaccarino A, et al. UbcH10 expression on thyroid fine-needle aspirates[J]. Cancer Cytopathol,2010; 118(3): 157-65.
[151]Donato G, Iofrida G, Lavano A, Volpentesta G, Signorelli F,Pallante PL, et al. Analysis of UbcH10 expression represents a useful tool for the diagnosis and therapy of astrocytic tumors[J]. Clin Neuropathol,2008;27(4):219-23.
[152]Karadag YS, Karadag O, Cicekli E, Ozturk S, Kiraz S,Ozbakir S, et al. Severity of carpal tunnel syndrome assessed with high frequency ultrasonography[J]. Rheumatol Int, 2010;30(6):761-5.
[153]Campone M, Campion L, Roche H, Gouraud W, Charbonnel C,Magrangeas F, et al. Prediction of metastatic relapse in nodepositive breast cancer:establishment of a clinicogenomic model after FEC100 adjuvant regimen[J]. Breast Cancer Res Treat,2008; 109(3):491-501.
[154]Taylor KJ, Sims AH, Liang L, Faratian D, Muir M,Walker G, et al.Dynamic changes in gene expression in vivo predict prognosis of tamoxifen-treated patients with breast cancer[J]. Breast Cancer Res,2010;12(3):R39.
[155]Wang H, Zhang C, Rorick A, Wu D, Chiu M, Thomas-Ahner J, et al. CCI-779 inhibits cell-cycle G2-M progression and invasion of castration-resistant prostate cancer via attenuation of UBE2C transcription and mRNA stability[J]. Cancer Res,2011;71(14): 4866-76.
[156]Zirn B, Samans B, Spangenberg C, Graf N, Eilers M, Gessler M.All-trans retinoic acid treatment of Wilms tumor cells reverses expression of genes associated with high risk and relapse in vivo[J].Oncogene,2005;24(33):5246-51.
[1]Jesenberger V, Jentsch S. Deadly encounter:ubiquitin meets apoptosis[J]. Nat Rev Mol Cell Biol,2002;3(2):112-21.
[2]Williamson A, Wickliffe KE, Mellone BG, Song L, Karpen GH,Rape M. Identification of a physiological E2 module for the human anaphase-promoting complex[J]. Proc Natl Acad Sci USA,2009; 106(43):18213-8.
[3]Kerscher O, Felberbaum R, Hochstrasser M.Modification of proteins by ubiquitin and ubiquitin-like proteins[A]. Annu Rev Cell Dev Biol,2006;22:159-80.
[4]Liu YC. Ubiquitin ligases and the immune response[A]. Annu Rev Immunol, 2004;22:81-127.
[5]Kimura Y, Tanaka K. Regulatory mechanisms involved in the control of ubiquitin homeostasis[J]. J Biochem,2010;147(6):793-8.
[6]Hicke L, Schubert HL, Hill CP. Ubiquitin-binding domains[J]. Nat Rev Mol Cell Biol, 2005;6(8):610-21.
[7]Stegmeier F, Rape M, Draviam VM, Nalepa G, Sowa ME, Ang XL, et al. Anaphase initiation is regulated by antagonistic ubiquitination and deubiquitination activities[J]. Nature.2007;446(7138):876-81.
[8]Reddy SK, Rape M.MarganskyWA, KirschnerMW. Ubiquitination by the anaphase-promoting complex drives spindle checkpoint inactivation[J]. Nature,2007; 446(7138):921-5.
[9]van Ree JH, Jeganathan KB, Malureanu L, van Deursen JM.Overexpression of the E2 ubiquitin-conjugating enzyme UbcH10 causes chromosome missegregation and tumor formation[J]. J Cell Biol,2010; 188(1):83-100.
[10]Townsley FM, Aristarkhov A, Beck S, Hershko A, Ruderman JV.Dominant-negative cyclin-selective ubiquitin carrier protein E2-C/UbcH10 blocks cells in metaphase[J]. Proc Natl Acad Sci USA.1997;94(6):2362-7.
[11]Kim S, Yu H. Mutual regulation between the spindle checkpoint and APC/C[J]. Semin Cell Dev Biol,2011;22(6):551-8.
[12]Nath S, Banerjee T, Sen D, Das T, Roychoudhury S. Spindle assembly checkpoint protein Cdc20 transcriptionally activates expression of ubiquitin carrier protein UbcH10[J]. J Biol Chem,2011;286(18):15666-77.
[13]Gauci S, Helbig AO, Slijper M, Krijgsveld J, Heck AJ, Mohammed S. Lys-N and trypsin cover complementary parts of the phosphoproteome in a refined SCX-based approach[J]. Anal Chem,2009;81(11):4493-501.
[14]Rape M, Kirschner MW. Autonomous regulation of the anaphasepromoting complex couples mitosis to S-phase entry[J]. Nature,2004;432(7017):588-95.
[15]Jin L,Williamson A,Banerjee S. Philipp I, Rape M. Mechanism of ubiquitin-chain formation by the human anaphase-promoting complex[J]. Cell,2008;133(4):653-65.
[16]David Y, Ziv T, Admon A, Navon A. The E2 ubiquitin-conjugating enzymes direct polyubiquitination to preferred lysines[J]. J Biol Chem,2010;285(12):8595-604.
[17]Nasmyth K. How do so few control so many[J]? Cell,2005;120(6):739-46.
[18]Yanagida M. Basic mechanism of eukaryotic chromosome segregation[J]. Philos Trans R Soc Lond B Biol Sci,2005;360(1455):609-21.
[19]Fang G. Checkpoint protein BubRl acts synergistically with Mad2 to inhibit anaphase-promoting complex[J]. Mol Biol Cell,2002; 13(3):755-66.
[20]Wickliffe KE, Lorenz S, Wemmer DE, Kuriyan J, Rape M. The mechanism of linkage-specific ubiquitin chain elongation by a single-subunit E2[J]. Cell,2011; 144(5):769-81.
[21]Murray AW. Recycling the cell cycle:cyclins revisited[J]. Cell,2004;116(2):221-34.
[22]Jackson PK, Eldridge AG, Freed E, Furstenthal L, Hsu JY, Kaiser BK, et al. The lore of the RINGs:substrate recognition and catalysis by ubiquitin ligases[J]. Trends Cell Biol,2000; 10(10):429-39.
[23]Jiang F, Basavappa R. Crystal structure of the cyclin-specific ubiquitin-conjugating enzyme from clam, E2-C, at 2.0 Aresolution[J].Biochemistry,1999;38(20):6471-8.
[24]Lin Y, Hwang WC, Basavappa R. Structural and functional analysis of the human mitotic-specific ubiquitin-conjugating enzyme,UbcH10[J]. J Biol Chem,2002;277(24): 21913-21.
[25]Summers MK, Pan B, Mukhyala K, Jackson PK. The unique N terminus of the UbcH10 E2 enzyme controls the threshold for APC activation and enhances checkpoint regulation of the APC[J]. Mol Cell,2008;31(4):544-56.
[26]Laurell C. Velazquez-Fernandez D, Lindsten K, Juhlin C. Enberg U. Geli J, et al. Transcriptional profiling enables molecular classification of adrenocortical tumours[J]. Eur J Endocrinol,2009;161(1):141-52.
[27]Loussouarn D, Campion L, Leclair F, Campone M, Charbonnel C,Ricolleau G. et al. Validation of UBE2C protein as a prognostic marker in node-positive breast cancer[J]. Br J Cancer.2009:101(1):166-73.
[28]Campone M, Campion L, Roche H, Gouraud W, Charbonnel C,Magrangeas F, et al. Prediction of metastatic relapse in nodepositive breast cancer:establishment of a clinicogenomic model after FEC100 adjuvant regimen[J]. Breast Cancer Res Treat,2008:109(3):491-501.
[29]Kamalakaran S, Varadan V, Giercksky Russnes HE, Levy D,Kendall J. Janevski A, et al. DNA methylation patterns in luminal breast cancers differ from non-luminal subtypes and can identify relapse risk independent of other clinical variables[J]. Mol Oncol,2011; 5(1):77-92.
[30]Parris TZ, Danielsson A. Nemes S. Kovacs A, Delle U. Fallenius G. et al. Clinical implications of gene dosage and gene expression patterns in diploid breast carcinoma[J]. Clin Cancer Res,2010;16(15):3860-74.
[31]Chen CC, Chang TW, Chen FM, Hou MF, Hung SY, Chong IW, et al. Combination of multiple mRNA markers (PTTG1,Survivin. UbcH10 and TK1) in the diagnosis of Taiwanese patients with breast cancer by membrane array [J]. Oncology,2006;70(6):438-46.
[32]Rajkumar T, Sabitha K, Vijayalakshmi N. Shirley S. Bose MV. Gopal G, et al. Identification and validation of genes involved in cervical tumourigenesis[J]. BMC Cancer, 2011;11:80.
[33]Narayan G, Bourdon V, Chaganti S, Arias-Pulido H, Nandula SV. Rao PH. et al. Gene dosage alterations revealed by cDNA microarray analysis in cervical cancer:identification of candidate amplified and overexpressed genes[J]. Genes Chromosomes Cancer,2007; 46(4):373-84.
[34]Chen S, Chen Y, Hu C, Jing H, Cao Y, Liu X. Association of clinicopathological features with UbcH10 expression in colorectal cancer[J]. J Cancer Res Clin Oncol, 2010;136(3):419-26.
[35]Bavi P, Uddin S, Ahmed M, Jehan Z, Bu R, Abubaker J. et al.Bortezomib stabilizes mitotic cyclins and prevents cell cycle progression via inhibition of UBE2C in colorectal carcinoma[J]. Am J Pathol,2011;178(5):2109-20.
[36]Sheffer M, Bacolod MD, Zuk O, Giardina SF. Pincas H, Barany F.et al. Association of survival and disease progression with chromosomal instability:a genomic exploration of colorectal cancer[J]. Proc Natl Acad Sci USA,2009; 106(17):7131-6.
[37]Lin J, Raoof DA, Wang Z, Lin MY. Thomas DG, Greenson JK, et al. Expression and effect of inhibition of the ubiquitin-conjugating enzyme E2C on esophageal adenocarcinoma[J], Neoplasia.2006;8(12):1062-71.
[38]leta K, Ojima E, Tanaka F, Nakamura Y. Haraguchi N, Mimori K,et al. Identification of overexpressed genes in hepatocellular carcinoma, with special reference to ubiquitin-conjugating enzyme E2C gene expression[J]. Int J Cancer,2007:121(1):33-8.
[39]Kadara H. Lacroix L, Behrens C. Solis L. Gu X. Lee JJ, et al.Idenlification of gene signatures and molecular markers for human lung cancer prognosis using an in vitro lung carcinogenesis system[J].Cancer Prev Res (Phila).2009;2(8):702-11.
[40]Berlingieri MT, Pallante P. Guida M, Nappi C, Masciullo V, Scambia G, et al. UbcH10 expression may be a useful tool in the prognosis of ovarian carcinomas[J]. Oncogene, 2007;26(14):2136-40.
[41]Wang Q, Li W. Zhang Y, Yuan X, Xu K. Yu J, et al. Androgen receptor regulates a distinct transcription program in androgenindependent prostate cancer[J]. Cell,2009;138(2):245-56.
[42]Cunha IW, Carvalho KC, Martins WK. Marques SM, Muto NH,Falzoni R, et al. Identification of genes associated with local aggressiveness and metastatic behavior in soft tissue tumors[J].Transl Oncol,2010;3(1):23-32.
[43]Guerriero E, Ferraro A, Desiderio D, Pallante P. Berlingieri MT, Iaccarino A, et al. UbcH10 expression on thyroid fine-needle aspirates[J]. Cancer Cytopathol, 2010;118(3):157-65.
[44]Lee JJ, Au AY, Foukakis T, Barbaro M, Kiss N, Clifton-Bligh R, et al. Array-CGH identifies cyclin Dl and UBCH10 amplicons in anaplastic thyroid carcinoma[J]. Endocr Relat Cancer,2008;15(3):801-15.
[45]Fevre-Montange M, Chain pier J, Durand A, Wierinckx A, Honnorat J, Guyotat J, et al. Microarray gene expression profiling in meningiomas:differential expression according to grade or histopathological subtype[J]. Int J Oncol,2009;35(6):1395-407.
[46]Bredel M, Bredel C, Juric D, Harsh GR, Vogel H, Recht LD, et al. Functional network analysis reveals extended gliomagenesis pathway maps and three novel MYC-interacting genes in human gliomas[J]. Cancer Res,2005;65(19):8679-89.
[47]Jiang L, Huang CG, Lu YC, Luo C, Hu GH, Liu HM, et al.Expression of ubiquitin-conjugating enzyme E2C/UbcH10 in astrocytic tumors[J]. Brain Res,2008; 1201: 161-6.
[48]Donato G, lofrida G. Lavano A, Volpentesta G, Signorelli F,Pallante PL, et al. Analysis of UbcH10 expression represents a useful tool for the diagnosis and therapy of astrocytic tumors[J]. Clin Neuropathol,2008;27(4):219-23.
[49]Okamoto Y, Ozaki T, Miyazaki K, Aoyama M, Miyazaki M,Nakagawara A. UbcH10 is the cancer-related E2 ubiquitinconjugating enzyme. Cancer Res.2003;63(14):4167-73.
[50]May WA, Arvand A, Thompson AD, Braun BS, Wright M, Denny CT. EWS/FLI1-induced manic fringe renders NIH 3T3 cells tumorigenic[J]. Nat Genet,1997; 17(4):495-7.
[51]Sudbo J, Lippman SM, Lee JJ, Mao L, Kildal W, Sudbo A, et al. The influence of resection and aneuploidy on mortality in oral leukoplakia[J]. N Engl J Med,2004;350(14):1405-13.
[52]Hanahan D,Weinberg RA. Hallmarks of cancer:the next generation[J].Cell,2011;144(5): 646-74.
[53]Kadara H, Behrens C, Yuan P, Solis L, Liu D, Gu X, et al. A five-gene and corresponding protein signature for stage-I lung adenocarcinoma prognosis[J]. Clin Cancer Res. 2011;17(6):1490-501.
[54]Hunter KD, Thurlow JK, Fleming J, Drake PJ, Vass JK. Kalna G, et al. Divergent routes to oral cancer[J]. Cancer Res,2006:66(15):7405-13.
[55]Patel D, McCance DJ. Compromised spindle assembly checkpoint due to altered expression of Ubch10 and Cdc20 in human papillomavirus type 16 E6-and E7-expressing keratinocytes[J]. J Virol.2010:84(21):10956-64.
[56]Wagner KW, Sapinoso LM, El-Rifai W, Frierson HF, Butz N,Mestan J, et al. Overexpression. genomic amplification and therapeutic potential of inhibiting the UbcH10 ubiquitin conjugase in human carcinomas of diverse anatomic origin[J], Oncogene,2004; 23(39):6621-9.
[57]Berlingieri MT, Pallante P, Sboner A, Barbareschi M. Bianco M.Ferraro A. et al. UbcH10 is overexpressed in malignant breast carcinomas[J]. Eur J Cancer.2007;43(18):2729-35.
[58]Pallante P, Berlingieri MT, Troncone G, Kruhoffer M, Orntoft TF. Viglietto G, et al. UbcH10 overexpression may represent a marker of anaplastic thyroid carcinomas[J]. Br J Cancer,2005;93(4):464-71.
[59]Chen Z, Zhang C, Wu D, Chen H, Rorick A, Zhang X, et al. Phospho-MED1-enhanced UBE2C locus looping drives castration-resistant prostate cancer growth[J]. EMBO J, 2011;30(12):2405-19.
[60]Garnis C, Coe BP, Lam SL, MacAulay C, Lam WL. Highresolution array CGH increases heterogeneity tolerance in the analysis of clinical samples[J]. Genomics,2005;85(6):790-3.
[61]Prochownik EV. c-Myc:linking transformation and genomic instability[J]. Curr Mol Med. 2008;8(6):446-58.
[62]Troncone G, Guerriero E, Pallante P, Berlingieri MT. Ferraro A,Del Vecchio L, et al. UbcH10 expression in human lymphomas[J].Histopathology,2009:54(6):731-40.
[63]Takahashi Y, Ishii Y, Nishida Y. Ikarashi M. Nagata T. Nakamura T. et al. Detection of aberrations of ubiquitin-conjugating enzyme E2C gene (UBE2C) in advanced colon cancer with liver metastases by DNA microarray and two-color FISH[J].Cancer Genet Cytogenet, 2006:168(1):30-5.
[64]Karadag YS, Karadag O, Cicekli E, Ozturk S, Kiraz S,Ozbakir S, et al. Severity of carpal tunnel syndrome assessed with high frequency ultrasonography[J]. Rheumatol Int. 2010;30(6):761-5.
[65]Taylor KJ, Sims AH, Liang L, Faratian D, Muir M,Walker G, et al.Dynamic changes in gene expression in vivo predict prognosis of tamoxifen-treated patients with breast cancer[J]. Breast Cancer Res,2010;12(3):R39.
[66]Wang H, Zhang C, Rorick A, Wu D, Chiu M, Thomas-Ahner J, et al. CCI-779 inhibits cell-cycle G2-M progression and invasion of castration-resistant prostate cancer via attenuation of UBE2C transcription and mRNA stability[J], Cancer Res,2011; 71(14): 4866-76.
[67]Zirn B, Samans B, Spangenberg C, Graf N, Eilers M, Gessler M.All-trans retinoic acid treatment of Wilms tumor cells reverses expression of genes associated with high risk and relapse in vivo[J].Oncogene,2005;24(33):5246-51.
[68]Lee EA, Keutmann MK, Dowling ML, Harris E, Chan G, Kao GD.Inactivation of the mitotic checkpoint as a determinant of the efficacy of microtubule-targeted drugs in killing human cancer cells[J]. Mol Cancer Ther,2004;3(6):661-9.
[2]WHO 2010.Viral cancer. Human papillomavirus [EB/OL], http://www.who.int/ vaccine-research/diseases/viral-cancers/en/index3.html.
[3]Parkin DM,Bray F.Ferlay J,Pisani P,Estimating the world emloer burden:GLOBOCAN 2000[J].ht Cancer,2001,94:153-156.
[4]黄莫婉.宫颈癌研究新进展.荸庆医学,2006.35：2185—2187.
[5]Wang SS,Sherman ME,Hildesheim A,et al.Cervical adenocarcinoma and squamous cell carcinoma incidence trends among white women and black women in the United States for 1976-2000[J].Cancer,2004,100:1035-1044.
[6]吴少雄.子宫颈癌放射治疗的几个热点问题[J].广东医学,2004,25(2)：120-121.
[7]Moyzis RK,et al.Proc Natl Acad sci USA,1988,85:6622-6626.
[8]Campbell LJ, Fidler C, Eagleton H, et al. hTERT, the catalytic component of telomerase, is downregulated in the haematopoietic stem cells of patients with chronic myeloid leukaemia. Leukemia,2006,20:671-9.
[9]Love WK, Berletch JB, Andrews LG et al. Epigenetic regulation of telomerase in retinoid-induced differentiation of human leukemia cells. Int J Oncol,2008,32(3):625-31.
[10]Linger J,Hughes TR,Shevchenko A,et al.Reverse transcriptase motifs in the catalytic subunit of telomerase [J].Science,1997,276 (5312):561-567.
[11]Daling JR,Madeleine MM,Mc Knight B,et al.The relationship of human papillomavirus-related cervical tumors to cigarette smoking,oral contraceptive use,and prior herpes simplex virus type 2 infection[J].Cancer Epidemiol Biomarkers Prev,1996,5:541-548.
[12]Bulk S, Berkhof J, Bulkmans NW,et al. Preferential risk of HPV16 for squamous cell carcinoma and of HPV18 for adenocarcinoma of the cervix compared to women with normal cytology in The Netherlands. Br J Cancer,2006 Jan 16;94(1):171-5.
[13]Kanaya T,Kyo S,Hamada K,et al. Adenoviral expression of p53 represses telomerase activity through down-regulation of human telomerase reverse transcriptase transcription[J]. Clin Cancer Res,2000,6(4):1239-1247.
[14]Jeong Seo E, Jang Kim H, Jae Lee C,et al.The role of HPV oncoproteins and cellular factors in maintenance of hTERT expression in cervicalcarcinoma ceHs.Gynecol Oncol,2004,94:40-47.
[15]Toshikuni N, Nouso K, Higashi T,et al. Expression of telomerase-associated protein 1 and telomerase reverse transcriptase in hepatocellular carcinoma. Br J Cancer.2000 Feb;82(4):833-7.
[16]Jong HS, Park YI, Kim S,et al. Up-regulation of human telomerase catalytic subunit during gastric carcinogenesis. Cancer.1999 Aug 15;86(4):559-65.
[17]CM Counter,M Meyerson,, EN Eaton,et al. Telomerase activity is restored in human cells by ectopic expression of hTERT(hEST2),the catalytic subunit of telomerase [J].Oncogene,Mar 1998,16(9):1217-22.
[18]A Wu. M Ichihashi,M Ueda,et al. Correlation of the expression of human teIomerase subunits with telomerase activity in normal skin and skin tumors [J]. Cancer,Nov 1999,86 (10):2038-44.
[19]Batinac T, Zamolo G, Hadzisejdic I. Telomerase in antitumor response. Med Hypotheses, 2007,68:128-30.
[20]Zawrocki A, Izycka-Swieszewska E, Papierz W,et al. Analysis of the prognostic significance of selected morphological and immunohistochemical markers in ependymomas, with literature review. Folia Neuropathol,2011;49(2):94-102.
[21]Zhang PH, Tu ZG, Yang MQ,et al. Experimental research of targeting hTERT gene inhibited in hepatocellular carcinoma therapy by RNA interference[J]. Ai Zheng,2004 Jun;23(6):619-25.
[22][39] Pallini R, Sorrentino A, Pierconti F, et al. Telomerase inhibition by stable RNA interference impairs tumor growth and angiogenesis in glioblastoma xenografts[J]. Int J Cancer,2006,118(9):2158-67.
[23]Calvin BH. Telomerase and cancer therapeutics. Nat Rev Cancer,2008,8(3):167-79.
[24]Li H, Zhou J, Miki J, et al. Telomerase-immortalized nonmalignant human prostate epithelial cells retain the properties of multipotent stem cells[J]. Exp Cell Res,2008, 314(l):92-102
[25]Lai SR, Phipps SM, Liu L, et al. Epigenetic control of telomerase and modes of telomere maintenance in aging and abnormal systems[J]. Front Biosci,2005,10:1779-96.
[26]Holm R, Skomedal H, Helland A,et al. Immunohistochemical analysis of p53 protein overexpression in normal, premalignant, and malignant tissues of the cervix uteri. J Pathol,1993 Jan; 169(1):21-6.
[27]Kanaya T,Kyo S,Hamada K,et al. Adenoviral expression of p53 represses telomerase activity through down-regulation of human telomerase reverse transcriptase transcription[J]. Clin Cancer Res,2000,6(4):1239-1247.
[28]Lai SR, Cunningham AP, Huynh VQ,et al. Evidence of extra-telomeric effects of hTERT and its regulation involving a feedback loop[J]. Exp Cell Res.2007 Jan 15;313(2):322-30.
[29]Shats I, Milyavsky M, Tang X.et al. p53-dependent down-regulation of telomerase is mediated by p21waf1[J].J Biol Chem.2004 Dec 3:279(49):50976-85.
[30]Xu DW,Wang Q,Gruber A, et al. Downregulation of telomerase reverse transcriptase mRNA expression by wild type p53 in human tumor cells. Oncogene.2000,19:5123-33.
[31]Beitzinger M, Oswald C, Beinoraviciute-Kellner R, et al.Regulation of telomerase activity by the p53 family member p73. Oncogene,2006,25:813-26.
[32]Mukherjee G, Freeman A, Moore R,et al. Biologic factors and response to radiotherapy in carcinoma of the cervix[J]. Int J Gynecol Cancer,2001 May-Jun;11(3):187-93.
[33]Suzuki Y, Nakano T, Ohno T, Oka K. Comparison of the radiobiological effect of carbon ion beam therapy and conventional radiation therapy on cervical cancer[J]. J Radiat Res,2008 Sep;49(5):473-9.
[34]Ishikawa H, Mitsuhashi N. Sakurai H,et al. The effects of p53 status and human papillomavirus infection on the clinical outcome of patients with stage ⅢB cervical carcinoma treated with radiation therapy alone[J]. Cancer.2001 Jan 1;91(1):80-9.
[35]Wickliffe K, Williamson A, Jin L, et al. The multiple layers of ubiquitin-dependent cell cycle control[J]. Chem Rev,2009,109(4):1537-1548.
[36]Hoeller D, Hecker CM, Dikic I. Ubiquitin and ubiquitin-like proteins in cancer pathogenesis[J]. Nat Rev Cancer,2006,6(10):776-788.
[37]Saville MK, Sparks A, Xirodimas DP, Wardrop J, Stevenson LF, Bourdon JC, et al. Regulation of p53 by the ubiquitin-conjugating enzymes UbcH5B/C in vivo. J Biol Chem,2004;279:42169-42181.
[38]Gonen H, Bercovich B, Orian A, Carrano A, Takizawa C, Yamanaka K, et al. Identification of the ubiquitin carrier proteins, E2s, involved in signal-induced conjugation and subsequent degradation of ikappaBalpha. J Biol Chem,1999;274:14823-14830.
[39]Okamoto Y, Ozaki T. Miyazaki K, et al. UbcH10 is the cancer-related E2 ubiquitin-conjugating enzyme[J]. Cancer Res,2003,63(14):4167-4173.
[40]Collado M, Garcia V, Garcia JM, Alonso I,et al. Genomic profiling of circulating plasma RNA for the analysis of cancer[J]. Clin Chem,2007 Oct;53(10):1860-3.
[41]Mohammed N, Rodriguez M, Garcia V,etal. EPAS1 mRNA in plasma from colorectal cancer patients is associated with poor outcome in advanced stages[J].Oncol Lett,2011 Jul;2(4):719-724.
[42]Ryan, K. M., Phillips, A. C., and Vousden, K. H. (2001) Curr. Opin. Cell Biol, 2013.332-337
[43]Oren, M. (2003) Cell Death Differ,10,431-442.
[44]Mittal MK, Singh K. Misra S, Chaudhuri G. SLUG-induced elevation of D1 cyclin in breast cancer cells through the inhibition of its ubiquitination[J]. J Biol Chem,2011 Jan 7;286(1):469-79.
[45]Ricke RM, van Ree JH, van Deursen JM. Whole chromosome instability and cancer:a complex relationship[J]. Trends Genet,2008,24(9):457-466.
[46]Van Ree JH, Jeganathan KB, Malureanu L, van Deursen JM.Overexpression of the E2 ubiquitin-conjugating enzyme UbcH10 causes chromosome missegregation and tumor formation. J Cell Biol,2010;188(1):83-100.
[47]Wagner KW, Sapinoso LM, E1-Rifai W, et al. Overexpression, genomic amplification and therapeutic potential of inhibiting the UbcH10 ubiquitin conjugase in human carcinomas of diverse anatomic origin[J]. Oncogene,2004,23(39):6621-6629.
[48]Chen S, Chen Y, Hu C, et al. Association of clinicopathological features with UbcH10 expression in colorectal cancer[J]. J Cancer ResClin Oncol,2010,136(3):419-426.
[49]Berlingieri MT, Pallante P, Sboner A,et al. UbcH10 is overexpressed in malignant breast carcinomas[J]. Eur J Cancer,2007 Dec;43(18):2729-35.
[50]Fujita T, Ikeda H, Taira N, et al. Overexpression of UbcH10 alternates the cell cycle profile and accelerate the tumor proliferation in colon cancer[J]. BMC Cancer,2009,9: 87.
[51]Fujita T, Ikeda H, Kawasaki K, et al. Clinicopathological relevance of UbcH10 in breast cancer[J]. Cancer Sci,2009,100(2):238-248.
[52]Shi R, Zhao Z, Gao Y,et al. Analysis and verification of the interaction network of differentially expressed genes in invasive bladder cancer [J]. Nan Fang Yi Ke Da Xue Xue Bao,2010 Aug;30(8):1771-4.
[53]Vasiljevic A, Champier J, Figarella-Branger D, et al. Molecular characterization of central neurocytomas:Potential markers for tumor typing and progression [J]. Neuropathology, 2012 Jul 23.
[54]Li Y, Tang H, Sun Z, et al. Network-based approach identified cell cycle genes as predictor of overall survival in lung adenocarcinoma patients[J]. Lung Cancer,2013 Apr;80(1):91-8.
[55]Kadara H, Lacroix L, Behrens C,et al. Identification of gene signatures and molecular markers for human lung cancer prognosis using an in vitro lung carcinogenesis system[J]. Cancer Prev Res (Phila),2009 Aug;2(8):702-11.
[56]Laurell C, Velazquez-Fernandez D. Lindsten K,et al. Transcriptional profiling enables molecular classification of adrenocortical tumours[J]. Eur J Endocrinol,2009 Jul:161(1): 141-52.
[57]Rajkumar T, Sabitha K, Vijayalakshmi N.et al. Identification and validation of genes involved in cervical tumourigenesis[J]. BMC Cancer,2011 Feb 22;11:80.
[58]Garcia-Escudero R. Martinez-Cruz AB, Santos M, et al. Gene expression profiling of mouse p53-deficient epidermal carcinoma defines molecular determinants of human cancer malignancy[J]. Mol Cancer,2010 Jul 14;9:193.
[59]Fang W, Li X. Jiang Q,et al. Transcriptional patterns, biomarkers and pathways characterizing nasopharyngeal carcinoma of Southern China[J]. J Transl Med,2008 Jun 20;6:32.
[60]May WA, Arvand A, Thompson AD, Braun BS, Wright M, Denny CT. EWS/FLI1-induced manic fringe renders NIH 3T3 cells tumorigenic[J]. Nat Genet, 1997;17(4):495-7.
[61]Sudbo J, Lippman SM, Lee JJ, Mao L, Kildal W, Sudbo A, et al. The influence of resection and aneuploidy on mortality in oral leukoplakia[J].N Engl J Med,2004;350 (14):1405-13.
[62]Hanahan D.Weinberg RA. Hallmarks of cancer:the next generation [J]. Cell,2011;144(5):646-74.
[63]Kadara H, Behrens C, Yuan P, Solis L, Liu D, Gu X, et al. A five-gene and corresponding protein signature for stage-I lung adenocarcinoma prognosis[J]. Clin Cancer Res, 2011; 17(6):1490-501.
[64]Hunter KD, Thurlow JK, Fleming J, Drake PJ, Vass JK, Kalna G, et al. Divergent routes to oral cancer[J]. Cancer Res,2006;66(15):7405-13.
[65]Patel D, McCance DJ. Compromised spindle assembly checkpoint due to altered expression of Ubch10 and Cdc20 in human papillomavirus type 16 E6- and E7-expressing keratinocytes [J]. Virol,2010;84(21):10956-64.
[66]Min W, Wen-li M, Zhao-hui S,et al. Microarray analysis identifies differentially expressed genes induced by human papillomavirus type 18 E6 silencing RNA[J]. Int J Gynecol Cancer.2009 May;19(4):547-63.
[67]Reddy SK, Rape M, Margansky WA, et al. Ubiquitination by the anaphase-promoting complex drives spindle checkpoint inactivation[J]. Nature,2007,446(7138):921-925.
[68]Chen S. Chen Y, Hu C, et al.Association of clinicopathological features with UbcH10 expression in colorectal cancer[J]. J Cancer Res Clin Oncol,2010,136(3):419-426.
[69]Loussouarn D, Campion L, Leclair F, et al. Validation of UBE2C protein as a prognostic marker in node-positive breast cancer[J]. Br J Cancer,2009,101(1):166-173.
[70]Ieta K, Ojima E, Tanaka F, et al. Identification of overexpressed genes in hepatocellular carcinoma, with special reference to ubiquitin-conjugating enzyme E2C gene expression [J]. Int J Cancer,2007,121(1):33-38.
[71]Wagner KW, Sapinoso LM, El-Rifai W, et al. Overexpression, genomic amplification and therapeutic potential of inhibiting the UbcH10 ubiquitin conjugase in human carcinomas of diverse anatomic origin[J]. Oncogene,2004,23(39):6621-6629.
[72]Troncone G, Guerriero E, Pallante P, et al. UbcHIO expression in human lymphomas[J]. Histopathology,2009,54(6):731-740.
[73]Shembade N, Ma A, Harhaj EW. Inhibition of NF-kappaB signaling by A20 through disruption of ubiquitin enzyme complexes[J]. Science,2010 Feb 26;327(5969):1135-9.
[74]Zhang S, Zhou Y, Sarkeshik A,et al. Identification of RNF8 as a ubiquitin ligase involved in targeting the p12 subunit of DNA polymerase δ for degradation in response to DNA damage[J]. J Biol Chem,2013 Feb 1;288(5):2941-50.
[75]Anan T, Nagata Y, Koga H,et al. Human ubiquitin-protein ligase Nedd4:expression, subcellular localization and selective interaction with ubiquitin-conjugating enzymes[J]. Genes Cells,1998 Nov;3(11):751-63.
[76]Page RC, Pruneda JN, Amick J,et al. Structural insights into the conformation and oligomerization of E2-ubiquitin conjugates[J]. Biochemistry.2012 May 22;51(20): 4175-87.
[77]Furukawa M, Ohta T, Xiong Y. Activation of UBC5 ubiquitin-conjugating enzyme by the RING finger of ROC1 and assembly of active ubiquitin ligases by all cullins[J].J Biol Chem,2002 May 3;277(18):15758-65.
[78]Zhang X, Zhao H, Chen Y,et al. Characterization and biological function analysis of the trim3a gene from zebrafish (Danio rerio)[J]. Fish Shellfish Immunol.2012 May;32(5): 621-8.
[79]Bentley ML, Corn JE, Dong KC,et al. Recognition of UbcH5c and the nucleosome by the Bmil/Ringlb ubiquitin ligase complex[J]. EMBO J,2011 Jul 19;30(16):3285-97.
[80]Pruneda JN, Stoll K.E, Bolton LJ,et al. Ubiquitin in motion:structural studies of the ubiquitin-conjugating enzyme-ubiquitin conjugate[J]. Biochemistry,2011 Mar 15; 50(10): 1624-33.
[81]Benirschke RC, Thompson JR, Nomine Y,et al. Molecular basis for the association of human E4B U box ubiquitin ligase with E2-conjugating enzymes UbcH5c and Ubc4[J]. Structure,2010 Aug 11;18(8):955-65.
[82]Nordquist KA, Dimitrova YN, Brzovic PS.et al. Structural and functional characterization of the monomeric U-box domain from E4B[J]. Biochemistry,2010 Jan 19;49(2):347-55.
[83]Xia ZP, Sun L, Chen X, Pineda G,et al. Direct activation of protein kinases by unanchored polyubiquitin chains[J]. Nature,2009 Sep 3;461(7260):114-9.
[84]Kubori T, Hyakutake A, Nagai H. Legionella translocates an E3 ubiquitin ligase that has multiple U-boxes with distinct functions[J]. Mol Microbiol,2008 Mar;67(6):1307-19.
[85]Zhang Y. Higashide WM, McCormick BA, Chen J, Zhou D. The inflammation-associated Salmonella SopA is a HECT-like E3 ubiquitin ligase[J]. Mol Microbiol.2006 Nov;62(3): 786-93.
[86]Zhang S,Zhou Y, Sarkeshik A,et al. Identification of RNF8 as a ubiquitin ligase involved in targeting the p12 subunit of DNA polymerase δ for degradation in response to DNA damage[J]. J Biol Chem,2013 Feb 1;288(5):2941-50.
[87]Ohbayashi N, Okada K, Kawakami S,et al. Physical and functional interactions between ZIP kinase and UbcH5[J]. Biochem Biophys Res Commun,2008 Aug 8;372(4):708-12.
[88]Knipscheer P, van Dijk WJ, Olsen JV, et al. Noncovalent interaction between Ubc9 and SUMO promotes SUMO chain formation[J]. EMBO J,2007 Jun 6;26(11):2797-807.
[89]Starita LM, Pruneda JN, Lo RS,et al. Activity-enhancing mutations in an E3 ubiquitin ligase identified by high-throughput mutagenesis[J]. Proc Natl Acad Sci U S A.2013 Mar 18.
[90]Brzovic PS, Keeffe JR, Nishikawa H.et al. Binding and recognition in the assembly of an active BRCA1/BARD1 ubiquitin-ligase complex[J].Proc Natl Acad Sci U S A,2003 May 13;100(10):5646-51.
[91]Polanowska J, Martin JS, Garcia-Muse T,et al. A conserved pathway to activate BRCA1-dependent ubiquitylation at DNA damage sites[J], EMBO J,2006 May 17,25(10): 2178-88.
[92]Brzovic PS, Lissounov A. Christensen DE,et al. A UbcH5/ubiquitin noncovalent complex is required for processive BRCA1-directed ubiquitination[J]. Mol Cell.2006 Mar 17;21(6):873-80.
[93]Nishito Y, Hasegawa M, Inohara N, Nunez G. MEX is a testis-specific E3 ubiquitin ligase that promotes death receptor-induced apoptosis[J]. Biochem J,2006 Jun 15;396(3):411-7.
[94]Wang Z. Chua HK, Gusti AA.et al. RING-H2 protein WSSV249 from white spot syndrome virus sequesters a shrimp ubiquitin-conjugating enzyme, PvUbc. for viral pathogenesis[J]. J Virol,2005 Jul;79(14):8764-72.
[95]Huang J, Huang Q, Zhou X, Shen MM.et al. The poxvirus p28 virulence factor is an E3 ubiquitin ligase[J]. J Biol Chem,2004 Dec 24;279(52):54110-6.
[96]Rajendra R, Malegaonkar D, Pungaliya P.et al. Topors functions as an E3 ubiquitin ligase with specific E2 enzymes and ubiquitinates p53[J]. J Biol Chem,2004 Aug 27;279(35): 36440-4.
[97]Wu K, Kovacev J, Pan ZQ. Priming and extending:a UbcH5/Cdc34 E2 handoff mechanism for polyubiquitination on a SCF substrate[J]. Mol Cell,2010 Mar 26;37(6): 784-96.
[98]Chiba T, Fujita S, Kubota H, Inoue D,et al. Identification of fasting-induced genes in the rat hypothalamus:relationship with neuroprotection[J]. Ann N Y Acad Sci,2007 Nov;1119:216-26.
[99]Hattori H, Zhang X, Jia Y,et al. RNAi screen identifies UBE2D3 as a mediator of all-trans retinoic acid-induced cell growth arrest in human acute promyelocytic NB4 cells[J]. Blood,2007 Jul 15;110(2):640-50.
[100]Qiu XB, Markant SL, Yuan J, Goldberg AL. Nrdpl-mediated degradation of the gigantic IAP, BRUCE, is a novel pathway for triggering apoptosis[J]. EMBO J,2004 Feb 25;23(4): 800-10.
[101]Yogosawa S, Miyauchi Y, Honda R,et al. Mammalian Numb is a target protein of Mdm2, ubiquitin ligase[J]. Biochem Biophys Res Commun.2003 Mar 21;302(4):869-72.
[102]Murata S, Minami Y, Minami M, Chiba T,et L. CHIP is a chaperone-dependent E3 ligase that ubiquitylates unfolded protein[J]. EMBO Rep,2001 Dec;2(12):1133-8.
[103]Honda Y, Tojo M, Matsuzaki K, Anan T,et al. Cooperation of HECT-domain ubiquitin ligase hHYD and DNA topoisomerase II-binding protein for DNA damage response[J]. J Biol Chem,2002 Feb 1;277(5):3599-605.
[104]Jensen JP, Bates PW, Yang M,et al. Identification of a family of closely related human ubiquitin conjugating enzymes[J]. J Biol Chem,1995 Dec 22;270(51):30408-14.
[105]Tokumoto M, Fujiwara Y, Shimada A,et al. Cadmium toxicity is caused by accumulation of p53 through the down-regulation of Ube2d family genes in vitro and in vivo[J]. J Toxicol Sci,2011 Apr;36(2):191-200.
[106]Jacques C, Baris O, Prunier-Mirebeau D, Savagner F,et al. Two-step differential expression analysis reveals a new set of genes involved in thyroid oncocytic tumors[J]. J Clin Endocrinol Metab,2005 Apr;90(4):2314-20.
[107]Qiu D, Wang WL,et al.Prognostic significance of hTERT mRNA quantitative expression in resected gastric carcinomas[J].Zhonghua Zhong Liu Za Zhi.2011 Jan;33(1):32-6.
[108]Land H,Parada LF,Weinberg RA.Tumorigenic converses of primary embryo fibroblasts reguires at least two cooperating Oncogenes.Nature,1983,304:596-602.
[109]Slamon DJ,deKernion JB,Verma IM,et al.Expression of cellular oncogenes in human Malignancies.Science,1984.224:256-262.
[110]骆福添,胡孟璇.Cox模型在肿瘤预后因素分析中作用.癌症,1991,10：84—87.
[111]袁晓雁,郭社坷,崔文华.影响宫颈癌患者预后因素的临床分析：实用医药杂志,2007-02.No.02.
[112]Torabi M,Aquino SL,Harisinghani MG,et al.Current concepts in lymph node imaging.J Nucl Med,2004,45(9):1509.
[113]Benedef JL,Odicino F,Maisonneuve P,et al.Carcinoma of the cervix uteri.Int J Gynaecol Obstet,2006,95(Suppl 1):43-103.
[114]Peters JM. The anaphase promoting complex/cyclosome:a machine designed to destroy[J]. Nat Rev Mol Cell Biol,2006,7(9):644-656.
[115]Stegmeier F, Rape M, Draviam VM, Nalepa G, Sowa ME, Ang XL, et al. Anaphase initiation is regulated by antagonistic ubiquitination and deubiquitination activities. Nature,2007;446(7138):876-81.
[116]Nasmyth K. How do so few control so many? Cell,2005;120(6):739-46.
[117]Yanagida M. Basic mechanism of eukaryotic chromosome segregation. Philos Trans R Soc Lond B Biol Sci,2005;360(1455):609-21.
[118]Fang G. Checkpoint protein BubR1 acts synergistically with Mad2 to inhibit anaphase-promoting complex. Mol Biol Cell.2002;13(3):755-66.
[119]Walker A, Acquaviva C, Matsusaka T,et al. UbcH10 has a rate-limiting role in G1 phase but might not act in the spindle checkpoint or as part of an autonomous oscillator[J]. J Cell Sci,2008 Jul 15;121(Pt 14):2319-26.
[120]Jiang L, Bao Y, Luo C, et al. Knockdown of ubiquitin-conjugating enzyme E2C/UbcH10 expression by RNA interference inhibits glioma cell proliferation and enhances cell apoptosis in vitro[J]. J Cancer Res Clin Oncol,2010,136(2):211-217.
[121]Hu R, Lu C, Mostaghel EA,et al. Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer[J]. Cancer Res,2012 Jul 15;72(14):3457-62.
[122]Bose MV, Gopisetty G, Selvaluxmy G.et al. Dominant negative Ubiquitin-conjugating enzyme E2C sensitizes cervical cancer cells to radiation[J]. Int J Radiat Biol,2012 Sep;88(9):629-34.
[123]Fristrup N, Birkenkamp-Demtroder K, Reinert T,et al. Multicenter validation of cyclin Dl, MCM7, TRIM29, and UBE2C as prognostic protein markers in non-muscle-invasive bladder cancer[J]. Am J Pathol,2013 Feb;182(2):339-49.
[124]Shan W, Akinfenwa PY, Savannah KB,et al. A small-molecule inhibitor targeting the mitotic spindle checkpoint impairs the growth of uterine leiomyosarcoma[J]. Clin Cancer Res,2012 Jun 15;18(12):3352-65.
[125]Zhao M, Zhang NY, Zurawel A,et al. Degradation of some polyubiquitinated proteins requires an intrinsic proteasomal binding element in the substrates[J]. J Biol Chem,2010 Feb 12;285(7):4771-80.
[126]Townsley FM, Aristarkhov A, Beck S, Hershko A, Ruderman JV.Dominant-negative cyclin-selective ubiquitin carrier protein E2-C/UbcH10 blocks cells in metaphase[J]. Proc Natl Acad Sci USA,1997;94(6):2362-7.
[127]Kim S, Yu H. Mutual regulation between the spindle checkpoint and APC/C[J].Semin Cell Dev Biol,2011;22(6):551-8.
[128]Nath S, Banerjee T, Sen D, Das T, Roychoudhury S. Spindle assembly checkpoint protein Cdc20 transcriptionally activates expression of ubiquitin carrier protein UbcH10[J].J Biol Chem,2011;286(18):15666-77.
[129]Gauci S, Helbig AO, Slijper M, Krijgsveld J, Heck AJ, Mohammed S. Lys-N and trypsin cover complementary parts of the phosphoproteome in a refined SCX-based approach. Anal Chem,2009;81(11):4493-501.
[130]Rape M, Kirschner MW. Autonomous regulation of the anaphasepromoting complex couples mitosis to S-phase entry[J]. Nature,2004;432(7017):588-95.
[131]Jin L,Williamson A, Banerjee S, Philipp I, Rape M. Mechanism of ubiquitin-chain formation by the human anaphase-promoting complex[J]. Cell,2008;133(4):653-65.
[132]David Y, Ziv T, Admon A, Navon A. The E2 ubiquitin-conjugating enzymes direct polyubiquitination to preferred lysines[J]. J Biol Chem,2010;285(12):8595-604.
[133]Wickliffe KE, Lorenz S, Wemmer DE, Kuriyan J, Rape M. The mechanism of linkage-specific ubiquitin chain elongation by a single-subunit E2[J].Cell,2011; 144(5):769-81.
[134]Murray AW. Recycling the cell cycle:cyclins revisited[J]. Cell,2004;116(2):221-34.
[135]Jackson PK, Eldridge AG, Freed E, Furstenthal L, Hsu JY, Kaiser BK, et al. The lore of the RINGs:substrate recognition and catalysis by ubiquitin ligases[J]. Trends Cell Biol, 2000;10(10):429-39.
[136]Jiang F, Basavappa R. Crystal structure of the cyclin-specific ubiquitin-conjugating enzyme from clam, E2-C, at 2.0 A resolution[J].Biochemistry,1999;38(20):6471-8.
[137]Lin Y, Hwang WC, Basavappa R. Structural and functional analysis of the human mitotic-specific ubiquitin-conjugating enzyme, UbcH10[J].J Biol Chem,2002;277(24): 21913-21.
[138]Summers MK, Pan B, Mukhyala K, Jackson PK. The unique N terminus of the UbcH10 E2 enzyme controls the threshold for APC activation and enhances checkpoint regulation of the APC[J]. Mol Cell,2008;31(4):544-56.
[139]Berlingieri MT, Pallante P,Sboner A. Barbareschi M. Bianco M,Ferraro A,et al. UbcH10 is overexpressed in malignant breast carcinomas[J]. Eur J Cancer,2007;43(18):2729-35.
[140]Loussouarn D, Campion L, Leclair F, Campone M, Charbonnel C,Ricolleau G, et al. Validation of UBE2C protein as a prognostic marker in node-positive breast cancer[J]. Br J Cancer,2009;101(1):166-73.
[141]Berlingieri MT, Pallante P, Guida M, Nappi C, Masciullo V, Scambia G, et al. UbcH10 expression may be a useful tool in the prognosis of ovarian carcinomas[J]. Oncogene, 2007;26(14):2136-40.
[142]Chen S, Chen Y, Hu C, Jing H, Cao Y, Liu X. Association of clinicopathological features with UbcH10 expression in colorectal cancer[J]. J Cancer Res Clin Oncol,2010 136(3):419-26.
[143]Ieta K, Ojima E, Tanaka F, Nakamura Y, Haraguchi N, Mimori K,et al. Identification of overexpressed genes in hepatocellular carcinoma, with special reference to ubiquitin-conjugating enzyme E2C gene expression[J]. Int J Cancer,2007;121(1):338.
[144]Laurell C, Velazquez-Fernandez D, Lindsten K, Juhlin C, Enberg U, Geli J, et al. Transcriptional profiling enables molecular classification of adrenocortical tumours[J]. Eur J Endocrinol,2009; 161(1):141-52.
[145]Pallante P, Berlingieri MT, Troncone G, Kruhoffer M, Orntoft TF, Viglietto G, et al. UbcH10 overexpression may represent a marker of anaplastic thyroid carcinomas[J]. Br J Cancer,2005;93(4):464-71.
[146]Jiang L, Huang CG, Lu YC, Luo C, Hu GH, Liu HM, et al.Expression of ubiquitin-conjugating enzyme E2C/UbcH10 in astrocytic tumors[J]. Brain Res,2008; 1201:161-6.
[147]Garnis C, Coe BP, Lam SL, MacAulay C, Lam WL. Highresolution array CGH increases heterogeneity tolerance in the analysis of clinical samples[J]. Genomics,.2005;85(6): 790-3.
[148]Wang Q, Li W, Zhang Y, Yuan X. Xu K, Yu J, et al. Androgen receptor regulates a distinct transcription program in androgenindependent prostate cancer[J]. Cell, 2009;138(2):245-56.
[149]Chen Z, Zhang C, Wu D, Chen H, Rorick A, Zhang X, et al. Phospho-MED1-enhanced UBE2C locus looping drives castration-resistant prostate cancer growth[J]. EMBO J. 2011;30(12):2405-19.
[150]Guerriero E, Ferraro A, Desiderio D, Pallante P, Berlingieri MT, Iaccarino A, et al. UbcH10 expression on thyroid fine-needle aspirates[J]. Cancer Cytopathol,2010; 118(3): 157-65.
[151]Donato G, Iofrida G, Lavano A, Volpentesta G, Signorelli F,Pallante PL, et al. Analysis of UbcH10 expression represents a useful tool for the diagnosis and therapy of astrocytic tumors[J]. Clin Neuropathol,2008;27(4):219-23.
[152]Karadag YS, Karadag O, Cicekli E, Ozturk S, Kiraz S,Ozbakir S, et al. Severity of carpal tunnel syndrome assessed with high frequency ultrasonography[J]. Rheumatol Int, 2010;30(6):761-5.
[153]Campone M, Campion L, Roche H, Gouraud W, Charbonnel C,Magrangeas F, et al. Prediction of metastatic relapse in nodepositive breast cancer:establishment of a clinicogenomic model after FEC100 adjuvant regimen[J]. Breast Cancer Res Treat,2008; 109(3):491-501.
[154]Taylor KJ, Sims AH, Liang L, Faratian D, Muir M,Walker G, et al.Dynamic changes in gene expression in vivo predict prognosis of tamoxifen-treated patients with breast cancer[J]. Breast Cancer Res,2010;12(3):R39.
[155]Wang H, Zhang C, Rorick A, Wu D, Chiu M, Thomas-Ahner J, et al. CCI-779 inhibits cell-cycle G2-M progression and invasion of castration-resistant prostate cancer via attenuation of UBE2C transcription and mRNA stability[J]. Cancer Res,2011;71(14): 4866-76.
[156]Zirn B, Samans B, Spangenberg C, Graf N, Eilers M, Gessler M.All-trans retinoic acid treatment of Wilms tumor cells reverses expression of genes associated with high risk and relapse in vivo[J].Oncogene,2005;24(33):5246-51.
[1]Jesenberger V, Jentsch S. Deadly encounter:ubiquitin meets apoptosis[J]. Nat Rev Mol Cell Biol,2002;3(2):112-21.
[2]Williamson A, Wickliffe KE, Mellone BG, Song L, Karpen GH,Rape M. Identification of a physiological E2 module for the human anaphase-promoting complex[J]. Proc Natl Acad Sci USA,2009; 106(43):18213-8.
[3]Kerscher O, Felberbaum R, Hochstrasser M.Modification of proteins by ubiquitin and ubiquitin-like proteins[A]. Annu Rev Cell Dev Biol,2006;22:159-80.
[4]Liu YC. Ubiquitin ligases and the immune response[A]. Annu Rev Immunol, 2004;22:81-127.
[5]Kimura Y, Tanaka K. Regulatory mechanisms involved in the control of ubiquitin homeostasis[J]. J Biochem,2010;147(6):793-8.
[6]Hicke L, Schubert HL, Hill CP. Ubiquitin-binding domains[J]. Nat Rev Mol Cell Biol, 2005;6(8):610-21.
[7]Stegmeier F, Rape M, Draviam VM, Nalepa G, Sowa ME, Ang XL, et al. Anaphase initiation is regulated by antagonistic ubiquitination and deubiquitination activities[J]. Nature.2007;446(7138):876-81.
[8]Reddy SK, Rape M.MarganskyWA, KirschnerMW. Ubiquitination by the anaphase-promoting complex drives spindle checkpoint inactivation[J]. Nature,2007; 446(7138):921-5.
[9]van Ree JH, Jeganathan KB, Malureanu L, van Deursen JM.Overexpression of the E2 ubiquitin-conjugating enzyme UbcH10 causes chromosome missegregation and tumor formation[J]. J Cell Biol,2010; 188(1):83-100.
[10]Townsley FM, Aristarkhov A, Beck S, Hershko A, Ruderman JV.Dominant-negative cyclin-selective ubiquitin carrier protein E2-C/UbcH10 blocks cells in metaphase[J]. Proc Natl Acad Sci USA.1997;94(6):2362-7.
[11]Kim S, Yu H. Mutual regulation between the spindle checkpoint and APC/C[J]. Semin Cell Dev Biol,2011;22(6):551-8.
[12]Nath S, Banerjee T, Sen D, Das T, Roychoudhury S. Spindle assembly checkpoint protein Cdc20 transcriptionally activates expression of ubiquitin carrier protein UbcH10[J]. J Biol Chem,2011;286(18):15666-77.
[13]Gauci S, Helbig AO, Slijper M, Krijgsveld J, Heck AJ, Mohammed S. Lys-N and trypsin cover complementary parts of the phosphoproteome in a refined SCX-based approach[J]. Anal Chem,2009;81(11):4493-501.
[14]Rape M, Kirschner MW. Autonomous regulation of the anaphasepromoting complex couples mitosis to S-phase entry[J]. Nature,2004;432(7017):588-95.
[15]Jin L,Williamson A,Banerjee S. Philipp I, Rape M. Mechanism of ubiquitin-chain formation by the human anaphase-promoting complex[J]. Cell,2008;133(4):653-65.
[16]David Y, Ziv T, Admon A, Navon A. The E2 ubiquitin-conjugating enzymes direct polyubiquitination to preferred lysines[J]. J Biol Chem,2010;285(12):8595-604.
[17]Nasmyth K. How do so few control so many[J]? Cell,2005;120(6):739-46.
[18]Yanagida M. Basic mechanism of eukaryotic chromosome segregation[J]. Philos Trans R Soc Lond B Biol Sci,2005;360(1455):609-21.
[19]Fang G. Checkpoint protein BubRl acts synergistically with Mad2 to inhibit anaphase-promoting complex[J]. Mol Biol Cell,2002; 13(3):755-66.
[20]Wickliffe KE, Lorenz S, Wemmer DE, Kuriyan J, Rape M. The mechanism of linkage-specific ubiquitin chain elongation by a single-subunit E2[J]. Cell,2011; 144(5):769-81.
[21]Murray AW. Recycling the cell cycle:cyclins revisited[J]. Cell,2004;116(2):221-34.
[22]Jackson PK, Eldridge AG, Freed E, Furstenthal L, Hsu JY, Kaiser BK, et al. The lore of the RINGs:substrate recognition and catalysis by ubiquitin ligases[J]. Trends Cell Biol,2000; 10(10):429-39.
[23]Jiang F, Basavappa R. Crystal structure of the cyclin-specific ubiquitin-conjugating enzyme from clam, E2-C, at 2.0 Aresolution[J].Biochemistry,1999;38(20):6471-8.
[24]Lin Y, Hwang WC, Basavappa R. Structural and functional analysis of the human mitotic-specific ubiquitin-conjugating enzyme,UbcH10[J]. J Biol Chem,2002;277(24): 21913-21.
[25]Summers MK, Pan B, Mukhyala K, Jackson PK. The unique N terminus of the UbcH10 E2 enzyme controls the threshold for APC activation and enhances checkpoint regulation of the APC[J]. Mol Cell,2008;31(4):544-56.
[26]Laurell C. Velazquez-Fernandez D, Lindsten K, Juhlin C. Enberg U. Geli J, et al. Transcriptional profiling enables molecular classification of adrenocortical tumours[J]. Eur J Endocrinol,2009;161(1):141-52.
[27]Loussouarn D, Campion L, Leclair F, Campone M, Charbonnel C,Ricolleau G. et al. Validation of UBE2C protein as a prognostic marker in node-positive breast cancer[J]. Br J Cancer.2009:101(1):166-73.
[28]Campone M, Campion L, Roche H, Gouraud W, Charbonnel C,Magrangeas F, et al. Prediction of metastatic relapse in nodepositive breast cancer:establishment of a clinicogenomic model after FEC100 adjuvant regimen[J]. Breast Cancer Res Treat,2008:109(3):491-501.
[29]Kamalakaran S, Varadan V, Giercksky Russnes HE, Levy D,Kendall J. Janevski A, et al. DNA methylation patterns in luminal breast cancers differ from non-luminal subtypes and can identify relapse risk independent of other clinical variables[J]. Mol Oncol,2011; 5(1):77-92.
[30]Parris TZ, Danielsson A. Nemes S. Kovacs A, Delle U. Fallenius G. et al. Clinical implications of gene dosage and gene expression patterns in diploid breast carcinoma[J]. Clin Cancer Res,2010;16(15):3860-74.
[31]Chen CC, Chang TW, Chen FM, Hou MF, Hung SY, Chong IW, et al. Combination of multiple mRNA markers (PTTG1,Survivin. UbcH10 and TK1) in the diagnosis of Taiwanese patients with breast cancer by membrane array [J]. Oncology,2006;70(6):438-46.
[32]Rajkumar T, Sabitha K, Vijayalakshmi N. Shirley S. Bose MV. Gopal G, et al. Identification and validation of genes involved in cervical tumourigenesis[J]. BMC Cancer, 2011;11:80.
[33]Narayan G, Bourdon V, Chaganti S, Arias-Pulido H, Nandula SV. Rao PH. et al. Gene dosage alterations revealed by cDNA microarray analysis in cervical cancer:identification of candidate amplified and overexpressed genes[J]. Genes Chromosomes Cancer,2007; 46(4):373-84.
[34]Chen S, Chen Y, Hu C, Jing H, Cao Y, Liu X. Association of clinicopathological features with UbcH10 expression in colorectal cancer[J]. J Cancer Res Clin Oncol, 2010;136(3):419-26.
[35]Bavi P, Uddin S, Ahmed M, Jehan Z, Bu R, Abubaker J. et al.Bortezomib stabilizes mitotic cyclins and prevents cell cycle progression via inhibition of UBE2C in colorectal carcinoma[J]. Am J Pathol,2011;178(5):2109-20.
[36]Sheffer M, Bacolod MD, Zuk O, Giardina SF. Pincas H, Barany F.et al. Association of survival and disease progression with chromosomal instability:a genomic exploration of colorectal cancer[J]. Proc Natl Acad Sci USA,2009; 106(17):7131-6.
[37]Lin J, Raoof DA, Wang Z, Lin MY. Thomas DG, Greenson JK, et al. Expression and effect of inhibition of the ubiquitin-conjugating enzyme E2C on esophageal adenocarcinoma[J], Neoplasia.2006;8(12):1062-71.
[38]leta K, Ojima E, Tanaka F, Nakamura Y. Haraguchi N, Mimori K,et al. Identification of overexpressed genes in hepatocellular carcinoma, with special reference to ubiquitin-conjugating enzyme E2C gene expression[J]. Int J Cancer,2007:121(1):33-8.
[39]Kadara H. Lacroix L, Behrens C. Solis L. Gu X. Lee JJ, et al.Idenlification of gene signatures and molecular markers for human lung cancer prognosis using an in vitro lung carcinogenesis system[J].Cancer Prev Res (Phila).2009;2(8):702-11.
[40]Berlingieri MT, Pallante P. Guida M, Nappi C, Masciullo V, Scambia G, et al. UbcH10 expression may be a useful tool in the prognosis of ovarian carcinomas[J]. Oncogene, 2007;26(14):2136-40.
[41]Wang Q, Li W. Zhang Y, Yuan X, Xu K. Yu J, et al. Androgen receptor regulates a distinct transcription program in androgenindependent prostate cancer[J]. Cell,2009;138(2):245-56.
[42]Cunha IW, Carvalho KC, Martins WK. Marques SM, Muto NH,Falzoni R, et al. Identification of genes associated with local aggressiveness and metastatic behavior in soft tissue tumors[J].Transl Oncol,2010;3(1):23-32.
[43]Guerriero E, Ferraro A, Desiderio D, Pallante P. Berlingieri MT, Iaccarino A, et al. UbcH10 expression on thyroid fine-needle aspirates[J]. Cancer Cytopathol, 2010;118(3):157-65.
[44]Lee JJ, Au AY, Foukakis T, Barbaro M, Kiss N, Clifton-Bligh R, et al. Array-CGH identifies cyclin Dl and UBCH10 amplicons in anaplastic thyroid carcinoma[J]. Endocr Relat Cancer,2008;15(3):801-15.
[45]Fevre-Montange M, Chain pier J, Durand A, Wierinckx A, Honnorat J, Guyotat J, et al. Microarray gene expression profiling in meningiomas:differential expression according to grade or histopathological subtype[J]. Int J Oncol,2009;35(6):1395-407.
[46]Bredel M, Bredel C, Juric D, Harsh GR, Vogel H, Recht LD, et al. Functional network analysis reveals extended gliomagenesis pathway maps and three novel MYC-interacting genes in human gliomas[J]. Cancer Res,2005;65(19):8679-89.
[47]Jiang L, Huang CG, Lu YC, Luo C, Hu GH, Liu HM, et al.Expression of ubiquitin-conjugating enzyme E2C/UbcH10 in astrocytic tumors[J]. Brain Res,2008; 1201: 161-6.
[48]Donato G, lofrida G. Lavano A, Volpentesta G, Signorelli F,Pallante PL, et al. Analysis of UbcH10 expression represents a useful tool for the diagnosis and therapy of astrocytic tumors[J]. Clin Neuropathol,2008;27(4):219-23.
[49]Okamoto Y, Ozaki T, Miyazaki K, Aoyama M, Miyazaki M,Nakagawara A. UbcH10 is the cancer-related E2 ubiquitinconjugating enzyme. Cancer Res.2003;63(14):4167-73.
[50]May WA, Arvand A, Thompson AD, Braun BS, Wright M, Denny CT. EWS/FLI1-induced manic fringe renders NIH 3T3 cells tumorigenic[J]. Nat Genet,1997; 17(4):495-7.
[51]Sudbo J, Lippman SM, Lee JJ, Mao L, Kildal W, Sudbo A, et al. The influence of resection and aneuploidy on mortality in oral leukoplakia[J]. N Engl J Med,2004;350(14):1405-13.
[52]Hanahan D,Weinberg RA. Hallmarks of cancer:the next generation[J].Cell,2011;144(5): 646-74.
[53]Kadara H, Behrens C, Yuan P, Solis L, Liu D, Gu X, et al. A five-gene and corresponding protein signature for stage-I lung adenocarcinoma prognosis[J]. Clin Cancer Res. 2011;17(6):1490-501.
[54]Hunter KD, Thurlow JK, Fleming J, Drake PJ, Vass JK. Kalna G, et al. Divergent routes to oral cancer[J]. Cancer Res,2006:66(15):7405-13.
[55]Patel D, McCance DJ. Compromised spindle assembly checkpoint due to altered expression of Ubch10 and Cdc20 in human papillomavirus type 16 E6-and E7-expressing keratinocytes[J]. J Virol.2010:84(21):10956-64.
[56]Wagner KW, Sapinoso LM, El-Rifai W, Frierson HF, Butz N,Mestan J, et al. Overexpression. genomic amplification and therapeutic potential of inhibiting the UbcH10 ubiquitin conjugase in human carcinomas of diverse anatomic origin[J], Oncogene,2004; 23(39):6621-9.
[57]Berlingieri MT, Pallante P, Sboner A, Barbareschi M. Bianco M.Ferraro A. et al. UbcH10 is overexpressed in malignant breast carcinomas[J]. Eur J Cancer.2007;43(18):2729-35.
[58]Pallante P, Berlingieri MT, Troncone G, Kruhoffer M, Orntoft TF. Viglietto G, et al. UbcH10 overexpression may represent a marker of anaplastic thyroid carcinomas[J]. Br J Cancer,2005;93(4):464-71.
[59]Chen Z, Zhang C, Wu D, Chen H, Rorick A, Zhang X, et al. Phospho-MED1-enhanced UBE2C locus looping drives castration-resistant prostate cancer growth[J]. EMBO J, 2011;30(12):2405-19.
[60]Garnis C, Coe BP, Lam SL, MacAulay C, Lam WL. Highresolution array CGH increases heterogeneity tolerance in the analysis of clinical samples[J]. Genomics,2005;85(6):790-3.
[61]Prochownik EV. c-Myc:linking transformation and genomic instability[J]. Curr Mol Med. 2008;8(6):446-58.
[62]Troncone G, Guerriero E, Pallante P, Berlingieri MT. Ferraro A,Del Vecchio L, et al. UbcH10 expression in human lymphomas[J].Histopathology,2009:54(6):731-40.
[63]Takahashi Y, Ishii Y, Nishida Y. Ikarashi M. Nagata T. Nakamura T. et al. Detection of aberrations of ubiquitin-conjugating enzyme E2C gene (UBE2C) in advanced colon cancer with liver metastases by DNA microarray and two-color FISH[J].Cancer Genet Cytogenet, 2006:168(1):30-5.
[64]Karadag YS, Karadag O, Cicekli E, Ozturk S, Kiraz S,Ozbakir S, et al. Severity of carpal tunnel syndrome assessed with high frequency ultrasonography[J]. Rheumatol Int. 2010;30(6):761-5.
[65]Taylor KJ, Sims AH, Liang L, Faratian D, Muir M,Walker G, et al.Dynamic changes in gene expression in vivo predict prognosis of tamoxifen-treated patients with breast cancer[J]. Breast Cancer Res,2010;12(3):R39.
[66]Wang H, Zhang C, Rorick A, Wu D, Chiu M, Thomas-Ahner J, et al. CCI-779 inhibits cell-cycle G2-M progression and invasion of castration-resistant prostate cancer via attenuation of UBE2C transcription and mRNA stability[J], Cancer Res,2011; 71(14): 4866-76.
[67]Zirn B, Samans B, Spangenberg C, Graf N, Eilers M, Gessler M.All-trans retinoic acid treatment of Wilms tumor cells reverses expression of genes associated with high risk and relapse in vivo[J].Oncogene,2005;24(33):5246-51.
[68]Lee EA, Keutmann MK, Dowling ML, Harris E, Chan G, Kao GD.Inactivation of the mitotic checkpoint as a determinant of the efficacy of microtubule-targeted drugs in killing human cancer cells[J]. Mol Cancer Ther,2004;3(6):661-9.